<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia - Hwang, EC - 2019 | Cochrane Library</title> <meta content="Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia - Hwang, EC - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013143.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia - Hwang, EC - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013143.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013143.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia" name="citation_title"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="urohwang@gmail.com" name="citation_author_email"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Michael Borofsky" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Myung Ha Kim" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD013143.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/02/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013143.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013143.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013143.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Water; Ejaculation; Lower Urinary Tract Symptoms [etiology, *surgery]; Organ Size; Penile Erection; Prostate [pathology, *surgery]; Prostatic Hyperplasia [complications, *surgery]; Quality of Life; Retreatment [statistics &amp; numerical data]; Robotic Surgical Procedures [*methods]; Surgery, Computer‐Assisted [methods]; Transurethral Resection of Prostate" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013143.pub2&amp;doi=10.1002/14651858.CD013143.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013143\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013143\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013143.pub2",title:"Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia",firstPublishedDate:"Feb 13, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013143.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013143.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013143.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013143.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013143.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013143.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013143.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013143.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013143.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013143.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4164 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013143.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0135"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0080"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-sec-0129"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/appendices#CD013143-sec-0140"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/table_n/CD013143StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/table_n/CD013143StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#CD013143-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#CD013143-cr-0003">Jae Hung Jung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#CD013143-cr-0004">Michael Borofsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#CD013143-cr-0005">Myung Ha Kim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information#CD013143-cr-0006">Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information/en#CD013143-sec-0144">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 February 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013143.pub2">https://doi.org/10.1002/14651858.CD013143.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013143-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013143-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013143-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013143-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013143-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013143-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013143-abs-0001" lang="en"> <section id="CD013143-sec-0001"> <h3 class="title" id="CD013143-sec-0001">Background</h3> <p>New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Aquablation is a novel, minimally invasive, water‐based therapy, combining image guidance and robotics for the removal of prostatic tissue. </p> </section> <section id="CD013143-sec-0002"> <h3 class="title" id="CD013143-sec-0002">Objectives</h3> <p>To assess the effects of Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. </p> </section> <section id="CD013143-sec-0003"> <h3 class="title" id="CD013143-sec-0003">Search methods</h3> <p>We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 11 February 2019, with no restrictions on the language or status of publication. </p> </section> <section id="CD013143-sec-0004"> <h3 class="title" id="CD013143-sec-0004">Selection criteria</h3> <p>We included parallel‐group randomised controlled trials (RCTs) and cluster‐RCTs, as well as non‐randomised observational prospective studies with concurrent comparison groups in which participants with BPH who underwent Aquablation. </p> </section> <section id="CD013143-sec-0005"> <h3 class="title" id="CD013143-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion at each stage, and undertook data extraction and 'Risk of bias' and GRADE assessments of the certainty of the evidence. We considered review outcomes measured up to and including 12 months after randomisation as short‐term and beyond 12 months as long‐term. </p> </section> <section id="CD013143-sec-0006"> <h3 class="title" id="CD013143-sec-0006">Main results</h3> <p>We included one RCT with 184 participants comparing Aquablation to TURP. The mean age and International Prostate Symptom Score were 65.9 years and 22.6, respectively. The mean prostate volume was 53.2 mL. We only found short‐term data for all outcomes based on a single randomised trial. </p> <p><b>Primary outcomes</b> </p> <p>Up to 12 months, Aquablation likely results in a similar improvement in urologic symptom scores to TURP (mean difference (MD) −0.06, 95% confidence interval (CI) −2.51 to 2.39; participants = 174; moderate‐certainty evidence). We downgraded the evidence certainty by one level due to study limitations. Aquablation may also result in similar quality of life when compared to TURP (MD 0.27, 95% CI −0.24 to 0.78; participants = 174, low‐certainty evidence). We downgraded the evidence certainty by two levels due to study limitations and imprecision. Aquablation may result in little to no difference in major adverse events (risk ratio (RR) 0.84, 95% CI 0.31 to 2.26; participants = 181, very low‐certainty evidence) but we are very uncertain of this finding. This would correspond to 15 fewer major adverse events per 1000 participants (95% CI 64 fewer to 116 more). We downgraded the evidence certainty by one level for study limitations and two levels for imprecision. </p> <p><b>Secondary outcomes</b> </p> <p>Up to 12 months, Aquablation may result in little to no difference in retreatments (RR 1.68, 95% CI 0.18 to 15.83; participants = 181, very low‐certainty evidence) but we are very uncertain of this finding. This would correspond to 10 more retreatments per 1000 participants (95% CI 13 fewer to 228 more). We downgraded the evidence certainty by one level due to study limitations and two levels for imprecision. </p> <p>Aquablation may result in little to no difference in erectile function as measured by International Index of Erectile Function questionnaire Erectile Function domain compared to TURP (MD 2.31, 95% CI −0.63 to 5.25; participants = 64, very low‐certainty evidence), and may cause slightly less ejaculatory dysfunction than TURP, as measured by Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MD 2.57, 95% CI 0.60 to 4.53; participants = 121, very low‐certainty evidence). However, we are very uncertain of both findings. We downgraded the evidence certainty by two levels due to study limitations and one level for imprecision for both outcomes. </p> <p>We did not find other prospective, comparative studies comparing Aquablation to TURP or other procedures such as laser ablation, enucleation, or other minimally invasive therapies. </p> </section> <section id="CD013143-sec-0007"> <h3 class="title" id="CD013143-sec-0007">Authors' conclusions</h3> <p>Based on short‐term (up to 12 months) follow‐up, the effect of Aquablation on urological symptoms is probably similar to that of TURP (moderate‐certainty evidence). The effect on quality of life may also be similar (low‐certainty evidence). We are very uncertain whether patients undergoing Aquablation are at higher or lower risk for major adverse events (very low‐certainty evidence). We are very uncertain whether Aquablation may result in little to no difference in erectile function but offer a small improvement in preservation of ejaculatory function (both very low‐certainty evidence). These conclusions are based on a single study of men with a prostate volume up to 80 mL in size. Longer‐term data and comparisons with other modalities appear critical to a more thorough assessment of the role of Aquablation for the treatment of LUTS in men with BPH. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013143-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013143-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013143-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013143-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013143-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013143-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013143-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013143-abs-0004" lang="en"> <h3>Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia </h3> <p><b>Review question</b> </p> <p>How does Aquablation compare to other procedures in patients with bothersome urinary symptoms caused by an enlarged prostate? </p> <p><b>Background</b> </p> <p>An enlarged prostate may cause bothersome urinary tract symptoms, such as having to urinate often during the day or night, having a weak stream, and the feeling of not completely emptying the bladder. When lifestyle changes (like drinking less liquids) or medications do not help, men may choose to have surgery, such as a transurethral resection of the prostate. However, this procedure may cause unwanted effects, such as erection and ejaculation problems, or require retreatment. This review looks at the results of Aquablation, which is a newer treatment that uses high‐pressure water to remove prostate tissue and help with urinary tract symptoms. </p> <p><b>Study characteristics</b> </p> <p>We looked for all studies that compared Aquablation to transurethral resection of the prostate. We included both studies in chance decided how men were treated and studies in which men and their urologist decided. We searched for studies up to 11 February 2019. </p> <p><b>Key results</b> </p> <p>We found only one study in which chance decided how men were treated. The study compared Aquablation to transurethral resection of the prostate. On average, men were about 66 years old. We did not find any other studies. </p> <p>We found that Aquablation likely improves urinary symptoms similarly to transurethral resection of the prostate and may also lead to similar quality of life. Rates of unwanted serious effects may also be similar but we are very uncertain about this. </p> <p>Men who have Aquablation may have a similar risk of needing a repeat procedure as those having transurethral resection of the prostate but we are very uncertain of this finding. </p> <p>Aquablation may make little to no difference to erectile function but may have fewer issues with ejaculation, but we are very uncertain of both findings. </p> <p>These findings are based on a single study funded by the company that makes the device used for Aquablation. All data were limited to 12 months' follow‐up or less and prostate size was less than or equal to 80 mL. </p> <p><b>Certainty of the evidence</b> </p> <p>Our certainty about the evidence we found ranged from moderate to very low due to shortcomings in how the study was done and small study size. This means that we have either moderate, limited or very little confidence in the results, depending on the outcome. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013143-sec-0135" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013143-sec-0135"></div> <h3 class="title" id="CD013143-sec-0136">Implications for practice</h3> <section id="CD013143-sec-0136"> <p>Based on moderate‐ to very low‐certainty evidence, the short‐term effect of Aquablation appears similar to transurethral resection of the prostate (TURP) with regard to urologic symptom scores and quality of life. We are very uncertain about the true rate of major adverse events. Patients and decision‐makers should be aware that the available evidence for this newer technology stems from a single, relatively small randomised controlled trial (RCT), sponsored by the device maker. Follow‐up was limited to 12 months' duration, which may be insufficient to fully appreciate its comparative effectiveness, and prostate volume was 80 mL or less. </p> </section> <h3 class="title" id="CD013143-sec-0137">Implications for research</h3> <section id="CD013143-sec-0137"> <p>Our knowledge could be improved by focusing on the following issues.</p> <p> <ul id="CD013143-list-0032"> <li> <p>This review identified only one RCT to contribute to its findings, and conclusions are limited by concerns over imprecision and selective reporting bias. More rigorously conducted and transparently reported, larger studies are important. </p> </li> <li> <p>Future studies should compare Aquablation to other treatment forms in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), such as laser enucleation techniques, prostatic urethral lift, and robotic‐assisted simple prostatectomy, for example, in which there is increasing interest. </p> </li> <li> <p>Longer‐term data are expected from the included study (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). In addition, further, separate studies and well‐designed prospective observational studies with at least 12 months' follow‐up are needed. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013143-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013143-sec-0029"></div> <div class="table" id="CD013143-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aquablation compared to transurethral resection of the prostate for benign prostatic hyperplasia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with benign prostatic hyperplasia (BPH)<br/> <b>Setting:</b> multicenter (17 centres)/ multicountry (Australia 1, New Zealand 1, UK 3, USA 12)<br/> <b>Intervention:</b> Aquablation<br/> <b>Comparison:</b> transurethral resection of the prostate (TURP) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with TURP</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Aquablation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/> Assessed with: IPSS<br/> Scale from 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean urologic symptom score was −15.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 lower<br/> (2.51 lower to 2.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> Assessed with: IPSS‐QoL<br/> Scale from 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life was −3.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.27 higher<br/> (0.24 lower to 0.78 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> Assessed with: Clavien‐Dindo classification system (Grade III, IV and V complications)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>181<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.31 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 per 1000<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/> (64 fewer to 116 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Retreatment</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>181<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.68<br/> (0.18 to 15.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 more per 1000<br/> (13 fewer to 228 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erectile function</b> (sexually active men only)<br/> Assessed with: IIEF‐EF domain<br/> Scale from 1 (worst; severe erectile dysfunction) to 30 (best; no erectile dysfunction)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function (sexually active men only) was −2.73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.31 higher<br/> (0.63 lower to 5.25 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ejaculatory function</b> (sexually active men only)<br/> Assessed with: MSHQ‐EjD<br/> Scale from 1 (worst) to 15 (best)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean ejaculatory function (sexually active men only) was −2.642</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.57 higher<br/> (0.6 higher to 4.53 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BPH:</b> benign prostate hyperplasia; <b>CI:</b> confidence interval; <b>EF:</b> erectile function; <b>IIEF:</b> International index of erectile function; <b>IPSS:</b> International prostate symptom score; <b>MD:</b> mean difference; <b>MSHQ‐EjD:</b> Male Sexual Health Questionnaire for Ejaculatory Dysfunction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TURP:</b> transurethral resection of prostate; <b>QoL:</b> quality of life </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: high risk of performance and unclear risk of reporting bias.<br/> <sup>b</sup>Downgraded by one level for imprecision: confidence interval crosses assumed threshold of minimal clinically important difference.<br/> <sup>c</sup>Downgraded by two levels for imprecision: wide confidence interval crosses assumed threshold of minimal clinically important difference.<br/> <sup>d</sup>Control group risk estimates come from single estimates of included study control group. Relative effect based on available case analysis.<br/> <sup>e</sup>Downgraded by two levels for study limitations: high risk of performance and attrition bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013143-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013143-sec-0030"></div> <section id="CD013143-sec-0031"> <h3 class="title" id="CD013143-sec-0031">Description of the condition</h3> <p>The prostate gland is an organ approximately the size of a walnut that is located below the urinary bladder encircling the urethra (<a href="./references#CD013143-bbs2-0046" title="LeissnerKH , TisellLE . The weight of the human prostate. Scandinavian Journal of Urology and Nephrology1979;13(2):137‐42. [PUBMED: 90380] ">Leissner 1979</a>). Benign prostatic hyperplasia (BPH) is a histological diagnosis defined as an increased number of epithelial and stromal cells in the prostate; this may cause prostatic enlargement and subsequently compression of the urethra and obstruction (<a href="./references#CD013143-bbs2-0062" title="RoehrbornCG . Pathology of benign prostatic hyperplasia. International Journal of Impotence Research2008;20 Suppl 3:S11‐8. [PUBMED: 19002119] ">Roehrborn 2008a</a>). BPH may therefore develop with or without lower urinary tract symptoms (LUTS) in men over the age of 40 (<a href="./references#CD013143-bbs2-0018" title="DunphyC , LaorL , TeA , KaplanS , ChughtaiB . Relationship between depression and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Reviews in Urology2015;17(2):51‐7. [PUBMED: 27222640] ">Dunphy 2015</a>). Several suggestive risk factors are aging, familial history, changes in hormonal levels, elevated markers of inflammation and metabolic syndrome (<a href="./references#CD013143-bbs2-0068" title="RussoGI , CastelliT , UrziD , PriviteraS , LaVigneraS , CondorelliRA , et al. Emerging links between non‐neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: a systematic review. International Journal of Urology : Official Journal of the Japanese Urological Association2015;22(11):982‐90. [PUBMED: 26193757] ">Russo 2015</a>). BPH receives clinical significance when associated with bothersome LUTS (<a href="./references#CD013143-bbs2-0062" title="RoehrbornCG . Pathology of benign prostatic hyperplasia. International Journal of Impotence Research2008;20 Suppl 3:S11‐8. [PUBMED: 19002119] ">Roehrborn 2008a</a>). Symptom bother typically correlates with the number and severity of symptoms increased, which relates to both impairment of quality of life and seeking treatment (<a href="./references#CD013143-bbs2-0004" title="AgarwalA , EryuzluLN , CartwrightR , ThorlundK , TammelaTL , GuyattGH , et al. What is the most bothersome lower urinary tract symptom? Individual‐ and population‐level perspectives for both men and women. European Urology2014;65(6):1211‐7. [PUBMED: 24486308] ">Agarwal 2014</a>). </p> <p>Self‐administered questionnaires, namely the International Prostate Symptom Score (IPSS), include the quality‐of‐life domain to evaluate the relative degree of bother across all LUTS (<a href="./references#CD013143-bbs2-0008" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. [PUBMED: 7563343] ">Barry 1995</a>). One study reported that increasing LUTS severity was associated with worsening overall distress in men, using patient perception of bladder condition which is a single‐item global question, ranging from one, causes no problems at all, to six, causes severe problems (<a href="./references#CD013143-bbs2-0012" title="ChappleC , Castro‐DiazD , ChuangYC , LeeKS , LiaoL , LiuSP , et al. Prevalence of lower urinary tract symptoms in China, Taiwan, and South Korea: results from a cross‐sectional, population‐based study. Advances in Therapy2017;34(8):1953‐65. [PUBMED: 28687936] ">Chapple 2017</a>). In this Cochrane Review, we define the term BPH as prostatic enlargement with LUTS. </p> <p>Benign prostatic hyperplasia can progress over time and cause serious consequences, such as acute urinary retention, urinary tract infection, and upper urinary tract deterioration. BPH also results in a negative impact on public health, increased annual healthcare cost and a reduction in a person's quality of life (<a href="./references#CD013143-bbs2-0042" title="KaplanAL , AgarwalN , SetlurNP , TanHJ , NiedzwieckiD , McLaughlinN , et al. Measuring the cost of care in benign prostatic hyperplasia using time‐driven activity‐based costing (TDABC). Healthcare (Amsterdam, Netherlands)2015;3(1):43‐8. [PUBMED: 26179588] ">Kaplan 2015</a>; <a href="./references#CD013143-bbs2-0043" title="KozminskiMA , WeiJT , NelsonJ , KentDM . Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International2015;115(2):308‐16. [PUBMED: 24825577] ">Kozminski 2015</a>; <a href="./references#CD013143-bbs2-0050" title="MartinS , LangeK , HarenMT , TaylorAW , WittertG . Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. Journal of Urology2014;191(1):130‐7. [PUBMED: 23770136] ">Martin 2014</a>). In Europe, 30% of men over 50 years of age, equivalent to 26 million men, are affected by bothersome LUTS, including storage symptoms (such as urinary frequency, urgency, and nocturia) or voiding symptoms (such as urinary hesitancy, weak urinary stream, straining to void and prolonged voiding), or both. A yearly reported associated number of medical prescriptions is estimated to be around 11.6 million for 74 million men at risk from 2004 to 2008 (<a href="./references#CD013143-bbs2-0013" title="CornuJN , CussenotO , HaabF , LukacsB . A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology2010;58(3):450‐6. [PUBMED: 20554374] ">Cornu 2010</a>). The prevalence of LUTS, according to an international study involving 7588 men, was 18%, 29%, 40%, and 56% in men aged in their forties, fifties, sixties and seventies, respectively (<a href="./references#CD013143-bbs2-0036" title="HommaY , KawabeK , TsukamotoT , YamanakaH , OkadaK , OkajimaE , et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. International Journal of Urology : Official Journal of the Japanese Urological Association1997;4(1):40‐6. [PUBMED: 9179665] ">Homma 1997</a>). In the USA, 8 million men older than 50 years of age also suffer from BPH (<a href="./references#CD013143-bbs2-0063" title="RoehrbornCG . Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology2008;10(1):14‐25. [PUBMED: 18470272] ">Roehrborn 2008b</a>). </p> <section id="CD013143-sec-0032"> <h4 class="title">Diagnosis</h4> <p>The diagnosis of BPH is based on followed clinical features: a prostate enlargement, bothersome LUTS and no other identified causes for the urinary problems. The initial evaluation of BPH includes medical history, symptom score questionnaires (e.g. the IPSS), physical examination including a digital rectal examination, urinalysis, prostate‐specific antigen (PSA) blood test, and frequency volume chart (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). A digital rectal examination is an important examination and may help to determine the coexistence of prostate cancer (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>). Urinalysis is useful for differential diagnosis to urinary tract infection. Together with a digital rectal examination, a PSA test increases the detection rate of prostate cancer, but would be performed if life expectancy is greater than 10 years and if a diagnosis of prostate cancer would modify the management approach (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). The IPSS is used to assess urinary symptom severity and quality of life. It is also used to document subjective responses to treatment (<a href="./references#CD013143-bbs2-0007" title="BarryMJ , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57; discussion 1564. [PUBMED: 1279218] ">Barry 1992</a>; <a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>). Measurement of urinary flow rates and residual urine are helpful in diagnostic evaluation and treatment response (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>). A low maximum flow rate (Qmax) and a large post‐voided residuals (PVR) predict an increased risk of symptom progression (<a href="./references#CD013143-bbs2-0015" title="CrawfordED , WilsonSS , McConnellJD , SlawinKM , LieberMC , SmithJA , et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology2006;175(4):1422‐6; discussion 1426‐7. [PUBMED: 16516013] ">Crawford 2006</a>). Other tests, including radiologic imaging, pressure flow study and urethrocystoscopy, are recommended for the assessment of prostate volume or morphology and bladder function before surgical treatment (<a href="./references#CD013143-bbs2-0020" title="EganKB . The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America2016;43(3):289‐97. [PUBMED: 27476122] ">Egan 2016</a>; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). </p> </section> <section id="CD013143-sec-0033"> <h4 class="title">Treatment</h4> <p>Treatment decisions are based on the burden of symptoms and the degree of bother noted by the patient. Initial treatment options for BPH include conservative management (watchful waiting and lifestyle modification) and medication, such as alpha‐blockers and 5‐alpha reductase inhibitors (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). If patients have been refractory to conservative and medical treatment, or BPH causes subsequent complications, such as acute urinary retention, recurrent urinary tract infection, bladder stones or diverticula, hematuria, or renal insufficiency, surgical options are considered (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). Until the 1970s, the only option available to treat this condition and relieve LUTS was an open or endoscopic surgery with the aim of removing or resecting prostatic tissue to open up the blocked urethra (<a href="./references#CD013143-bbs2-0056" title="PariserJJ , PearceSM , PatelSG , BalesGT . National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology2015;86(4):721‐5. [PUBMED: 26276574] ">Pariser 2015</a>). Clinical guidelines recommend monopolar or bipolar transurethral resection of the prostate (TURP) as a standard treatment for subjective symptom relief and objective improvements in urinary flow (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). However, TURP can cause complications, such as dilutional hyponatraemia (known as TUR syndrome), sexual dysfunction including erectile dysfunction and anejaculation (more than 5%), bladder neck contracture, urinary tract infection and hematuria (<a href="./references#CD013143-bbs2-0059" title="ReichO , GratzkeC , BachmannA , SeitzM , SchlenkerB , HermanekP , et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. Journal of Urology2008;180(1):246‐9. [PUBMED: 18499179] ">Reich 2008</a>). Furthermore, BPH is a disease common in older men who have an increased risk of complications for general anaesthesia and the surgery itself (<a href="./references#CD013143-bbs2-0018" title="DunphyC , LaorL , TeA , KaplanS , ChughtaiB . Relationship between depression and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Reviews in Urology2015;17(2):51‐7. [PUBMED: 27222640] ">Dunphy 2015</a>; <a href="./references#CD013143-bbs2-0078" title="YooTK , ChoHJ . Benign prostatic hyperplasia: from bench to clinic. Korean Journal of Urology2012;53(3):139‐48. [PUBMED: 22468207] ">Yoo 2012</a>). Even though a systematic review reported that bipolar TURP alleviates these complications (<a href="./references#CD013143-bbs2-0055" title="OmarMI , LamTB , AlexanderCE , GrahamJ , MamoulakisC , ImamuraM , et al. Systematic review and meta‐analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU International2014;113(1):24‐35. [PUBMED: 24053602] ">Omar 2014</a>), these issues have contributed to the emergence of minimally invasive procedures using laser (laser ablation or enucleation), thermal delivery devices (microwave thermotherapy, radiofrequency, high‐intensity focused ultrasound, water vapour therapy), mechanical devices (prostatic stent, prostatic urethral lift), fractionation of prostatic tissue (histotripsy, Aquablation), prostate artery embolization, and intraprostatic drugs. Some of these methods can be carried out in an outpatient setting with local anaesthesia and acceptable adverse events (<a href="./references#CD013143-bbs2-0006" title="AounF , MarcelisQ , RoumeguereT . Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Research and Reports in Urology2015;7:125‐36. [PUBMED: 26317083] ">Aoun 2015</a>; <a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>). </p> </section> </section> <section id="CD013143-sec-0034"> <h3 class="title" id="CD013143-sec-0034">Description of the intervention</h3> <p>Aquablation is performed using the AquaBeam System (<a href="./references#CD013143-bbs2-0057" title="PROCEPT BioRobotics, Redwood Shores, California, USA. www.procept‐biorobotics.com. ">PROCEPT BioRobotics</a>). It is a novel, minimally invasive water ablation therapy for LUTS due to BPH, which combines image guidance and robotics for the removal of prostatic tissue. The Aquablation device consists of three main components: the conformal planning unit (CPU), the console and the robotic hand piece (<a href="#CD013143-fig-0001">Figure 1</a>). The procedure is largely automated and is performed under general anaesthesia (<a href="./references#CD013143-bbs2-0024" title="GillingP , ReutherR , KahokehrA , FraundorferM . Aquablation ‐ image‐guided robot‐assisted waterjet ablation of the prostate: initial clinical experience. BJU International2016;117(6):923‐9. [PUBMED: 26477826] ">Gilling 2016</a>; <a href="./references#CD013143-bbs2-0025" title="GillingP , AndersonP , TanA . Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1‐year results. Journal of Urology2017;197(6):1565‐72. [PUBMED: 28111300] ">Gilling 2017</a>). It involves introducing a custom 22 French (or Charrière; equivalent to 0.33 mm in diameter) rigid cystoscope into the bladder under direct vision with the aid of a visual obturator. The obturator is then removed from the cystoscope sheath, leaving the distal end of the sheath flush with the bladder neck. The Aquablation handpiece is advanced through the sheath until the distal end of the device is positioned in the bladder. The 15 mL balloon is then inflated with saline and retracted until it seals against the bladder neck, obstructing antegrade flow. The articulating arm is locked into place to securely anchor the handpiece within the prostate. Transrectal ultrasound is then performed and displayed on the CPU, enabling the operator to map the contour of the prostate and define the area of resection. Utilising the planning parameters entered into the CPU, the console generates and adjusts the saline pressure to allow for controlled resection of the prostate tissue (<a href="./references#CD013143-bbs2-0024" title="GillingP , ReutherR , KahokehrA , FraundorferM . Aquablation ‐ image‐guided robot‐assisted waterjet ablation of the prostate: initial clinical experience. BJU International2016;117(6):923‐9. [PUBMED: 26477826] ">Gilling 2016</a>; <a href="./references#CD013143-bbs2-0025" title="GillingP , AndersonP , TanA . Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1‐year results. Journal of Urology2017;197(6):1565‐72. [PUBMED: 28111300] ">Gilling 2017</a>). The system includes a peristaltic pump for active fluid aspiration to maintain intravesical volume equilibrium, and aspiration through the handpiece to enable sample collection for histological analysis (<a href="./references#CD013143-bbs2-0024" title="GillingP , ReutherR , KahokehrA , FraundorferM . Aquablation ‐ image‐guided robot‐assisted waterjet ablation of the prostate: initial clinical experience. BJU International2016;117(6):923‐9. [PUBMED: 26477826] ">Gilling 2016</a>; <a href="./references#CD013143-bbs2-0025" title="GillingP , AndersonP , TanA . Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1‐year results. Journal of Urology2017;197(6):1565‐72. [PUBMED: 28111300] ">Gilling 2017</a>). At completion of the procedure, the articulating arm is unlocked, and the device removed from the urethra. For the sake of haemostasis, a three‐way Foley catheter is placed into the bladder and inflated with 5 cc to 7 cc of saline. The balloon is pulled distally into the prostatic fossa, inflated to a total volume equalling the approximate volume removed during the Aquablation and kept at this inflation volume for two to five hours (<a href="./references#CD013143-bbs2-0005" title="AljuriN , GillingP , RoehrbornC . How I do it: balloon tamponade of prostatic fossa following Aquablation. Canadian Journal of Urology2017;24(4):8937‐40. [PUBMED: 28832316] ">Aljuri 2017</a>). However, during early experience with the Aquablation procedure, TUR‐coagulation was also used for haemostasis (<a href="./references#CD013143-bbs2-0025" title="GillingP , AndersonP , TanA . Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1‐year results. Journal of Urology2017;197(6):1565‐72. [PUBMED: 28111300] ">Gilling 2017</a>). </p> <div class="figure" id="CD013143-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="The current AquaBeam console, CPU, and robotic handpiece with an articulating armReproduced with permission from Springer Customer Service Centre GmbH: Springer Nature, Current Urology Reports, Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results, Omid Yassaie, Joshua A. Silverman, Peter J. Gilling, COPYRIGHT 2017" data-id="CD013143-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>The current AquaBeam console, CPU, and robotic handpiece with an articulating arm</p> <p>Reproduced with permission from Springer Customer Service Centre GmbH: Springer Nature, Current Urology Reports, Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results, Omid Yassaie, Joshua A. Silverman, Peter J. Gilling, COPYRIGHT 2017 </p> </div> </div> </div> <section id="CD013143-sec-0035"> <h4 class="title">Adverse events of the intervention</h4> <p>To date, experience with Aquablation is limited. Reported adverse events include postoperative pain, hematuria, urinary tract infections, urethral stricture disease, acute urinary retention and one instance of blood transfusion (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). The reported rates of reoperations is 2.5% (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). </p> </section> </section> <section id="CD013143-sec-0036"> <h3 class="title" id="CD013143-sec-0036">How the intervention might work</h3> <p>High‐pressure water jet technology has been adapted to dissect parenchymal tissues, which has been suggested to be safe and effective in the transurethral setting in the resection of bladder tumours (<a href="./references#CD013143-bbs2-0053" title="NageleU , KuglerM , NicklasA , MerseburgerAS , WalcherU , MikuzG , et al. Waterjet hydrodissection: first experiences and short‐term outcomes of a novel approach to bladder tumor resection. World Journal of Urology2011;29(4):423‐7. [PUBMED: 21305303] ">Nagele 2011</a>). The development of the Aquablation technology for BPH is based on the hypothesis that the high‐pressure water jet will preferentially ablate the adenomatous tissue, preserving collagenous structures such as the surgical capsule, bladder neck, and blood vessels. The Aquablation system delivers a conformal, quantifiable and standardised heat‐free ablation and thereby opens widely the patent prostatic urethra between the bladder neck and peripheral sphincter. There are two phases in the Aquablation system (<a href="./references#CD013143-bbs2-0022" title="FaberK , deAbreuAL , RamosP , AljuriN , MantriS , GillI , et al. Image‐guided robot‐assisted prostate ablation using water jet‐hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. Journal of Endourology2015;29(1):63‐9. [PUBMED: 25000418] ">Faber 2015</a>). In the first phase (the cutting mode) the surgeon has the ability to adjust the angle, length, contour and depth of penetration. Upon initiating the procedure, the console activates the pump that drives physiologic saline (0.9%) through the probe’s nozzle at pressures ranging from 500 to 8000 pounds per square inch (PSI), to cut and dissect soft tissue at the predetermined system parameters. In the second phase (the coagulation mode), the console drives the pump at low pressure (5 to 15 PSI) and activates the 2 watt (W) green light laser (532 nanometres) to allow for cauterisation after resection (<a href="./references#CD013143-bbs2-0022" title="FaberK , deAbreuAL , RamosP , AljuriN , MantriS , GillI , et al. Image‐guided robot‐assisted prostate ablation using water jet‐hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. Journal of Endourology2015;29(1):63‐9. [PUBMED: 25000418] ">Faber 2015</a>). </p> </section> <section id="CD013143-sec-0037"> <h3 class="title" id="CD013143-sec-0037">Why it is important to do this review</h3> <p>Minimally invasive surgery for BPH is a dynamic field, with novel treatment modalities emerging in experimental and clinical use with various safety and efficacy profiles. Aquablation is a new technology in terms of treatment of BPH, and reported experimental and clinical initial results suggest it is efficacious and well‐tolerated. However, it is unclear whether Aquablation actually translates into more clinical benefits and fewer adverse events in clinical practice compared to conventional surgical treatment. In addition, no systematic review so far has used the same rigorous methodology as a Cochrane Review, which includes the application of the GRADE approach and its focus on patient‐important outcomes (<a href="./references#CD013143-bbs2-0027" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. [PUBMED: 18456631] '>Guyatt 2008</a>). In today's era, with the availability of numerous minimally invasive procedures to treat BPH, the findings of this Cochrane Review will be highly relevant to policymakers, healthcare providers and patients alike. We expect this review to complement a suite of related Cochrane Reviews focused on the endourological management (<a href="./references#CD013143-bbs2-0039" title="JungJH , McCutcheonKA , ReddyB , BorofskyM , NarayanV , KimMH , et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2017, Issue 10. [DOI: 10.1002/14651858.CD012832] ">Jung 2017a</a>) and vascular management (<a href="./references#CD013143-bbs2-0040" title="JungJH , ShinTY , McCutcheonKA , BorofskyM , NarayanV , YoungS , et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD012867] ">Jung 2017b</a>) of LUTS related to BPH. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013143-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013143-sec-0038"></div> <p>To assess the effects of Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013143-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013143-sec-0039"></div> <section id="CD013143-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013143-sec-0041"> <h4 class="title">Types of studies</h4> <p>This review is based on a published protocol (<a href="./references#CD013143-bbs2-0079" title="HwangEC , JungJH , BorofskyM , KimMH , DahmP . Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2018, Issue 10. [DOI: 10.1002/14651858.CD013143] ">Hwang 2018</a>). For details on the differences between that protocol and this review, please refer to the <a href="#CD013143-sec-0148">Differences between protocol and review</a> section. We included parallel‐group RCTs and cluster‐RCTs. We excluded cross‐over trials, as these study designs are not relevant in this setting. If we only found RCTs that provided low‐certainty evidence for a given outcome or comparison (e.g. limited information about adverse events and long‐term effects), we planned to include non‐RCTs as a source of complementary, sequential, or replacement evidence for RCTs. However, we limited this to prospective cohort studies with concurrent comparison groups, which are similar to relevant RCTs (<a href="./references#CD013143-bbs2-0069" title="SchünemannHJ , TugwellP , ReevesBC , AklEA , SantessoN , SpencerFA , et al. Non‐randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Research Synthesis Methods2013;4(1):49‐62. [PUBMED: 26053539] ">Schünemann 2013</a>; <a href="./references#CD013143-bbs2-0073" title="SterneJA , HernanMA , ReevesBC , SavovicJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016;355:i4919. [PUBMED: 27733354] ">Sterne 2016a</a>; <a href="./references#CD013143-bbs2-0074" title="SterneJA , HigginsJP , ElbersRG , Reeves BC and the development group for ROBINS‐I. Risk of bias in non‐randomized studies of interventions (ROBINS‐I): detailed guidance, updated 12 October 2016. Available from www.riskofbias.info (accessed 6 July 2018). ">Sterne 2016b</a>). We did not include single‐armed studies. We included studies regardless of their publication status or language. </p> </section> <section id="CD013143-sec-0042"> <h4 class="title">Types of participants</h4> <p>We defined the eligible patient population as men over the age of 40 years with a prostate volume of 20 mL or greater (as assessed by ultrasound or cross‐sectional imaging), with LUTS as determined by International Prostate Symptom Scores (IPSS) of eight or over, and a maximum flow rate (Q<sub>max</sub>) of less than 15 mL/second, as measured by non‐invasive uroflowmetry, invasive pressure flow studies, or both (<a href="./references#CD013143-bbs2-0018" title="DunphyC , LaorL , TeA , KaplanS , ChughtaiB . Relationship between depression and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Reviews in Urology2015;17(2):51‐7. [PUBMED: 27222640] ">Dunphy 2015</a>; <a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0051" title="McNicholasTA . Benign prostatic hyperplasia and new treatment options ‐ a critical appraisal of the UroLift system. Medical Devices (Auckland, N.Z.)2016;9:115‐23. [PUBMED: 27274321] ">McNicholas 2016</a>; <a href="./references#CD013143-bbs2-0052" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793‐803. [PUBMED: 21420124] ">McVary 2011</a>). We based the age limitation on the fact that the prevalence of BPH increases in middle‐aged and older men and is infrequent in younger men (<a href="./references#CD013143-bbs2-0009" title="BarryMJ , FowlerFJJr , BinL , PittsJC3rd , HarrisCJ , MulleyAGJr . The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology1997;157(1):10‐4; discussion 14‐5. [PUBMED: 8976204] ">Barry 1997</a>; <a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>; <a href="./references#CD013143-bbs2-0020" title="EganKB . The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America2016;43(3):289‐97. [PUBMED: 27476122] ">Egan 2016</a>). We included studies in which only a subset of participants was relevant to this review (i.e. studies with more than 75% of participants only as relevant to the review), if data were available separately for the relevant subset. </p> <p>We excluded studies that included men with active urinary tract infection, bacterial prostatitis, chronic renal failure, untreated bladder calculi or large diverticula, prostate cancer, and urethral stricture disease, as well as those who had undergone prior prostate, bladder neck, or urethral surgery. We also excluded studies of people with other conditions that affect urinary symptoms, such as neurogenic bladder due to spinal cord injury, multiple sclerosis, or central nervous system disease. </p> </section> <section id="CD013143-sec-0043"> <h4 class="title">Types of interventions</h4> <section id="CD013143-sec-0044"> <h5 class="title">Experimental intervention</h5> <p> <ul id="CD013143-list-0001"> <li> <p>Aquablation</p> </li> </ul> </p> </section> <section id="CD013143-sec-0045"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD013143-list-0002"> <li> <p>Sham control (or no intervention)</p> </li> <li> <p>Transurethral resection of the prostate (TURP) (monopolar or bipolar)</p> </li> <li> <p>Laser ablations of the prostate (e.g. photoselective vaporisation of the prostate)</p> </li> <li> <p>Laser enucleations of the prostate (e.g. Holmium laser enucleation of the prostate (HoLEP)) </p> </li> <li> <p>Prostatic urethral lift (PUL)</p> </li> <li> <p>Convective radiofrequency water vapour thermal therapy (e.g. Rezum)</p> </li> <li> <p>Other minimally invasive therapies (e.g. transurethral incision of the prostate, transurethral thermal ablation of the prostate (needle ablation, microwave therapy, and radiofrequency ablative techniques), prostate stent, and prostatic arterial embolization) </p> </li> <li> <p>Simple prostatectomy (e.g. open, laparoscopic, and robotic‐assisted prostatectomy)</p> </li> </ul> </p> <p>We planned to investigate the following comparisons of experimental interventions versus comparator interventions. Concomitant interventions had to be the same in the experimental and comparator groups in order to establish fair comparisons. </p> </section> <section id="CD013143-sec-0046"> <h5 class="title">Comparisons</h5> <p> <ul id="CD013143-list-0003"> <li> <p>Aquablation versus sham control (or no intervention)</p> </li> <li> <p>Aquablation versus TURP</p> </li> <li> <p>Aquablation versus laser ablations of the prostate</p> </li> <li> <p>Aquablation versus laser enucleations of the prostate</p> </li> <li> <p>Aquablation versus PUL</p> </li> <li> <p>Aquablation versus convective radiofrequency water vapour thermal therapy</p> </li> <li> <p>Aquablation versus other minimally invasive therapies</p> </li> <li> <p>Aquablation versus simple prostatectomy</p> </li> </ul> </p> </section> </section> <section id="CD013143-sec-0047"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the measurement of the outcomes assessed in this review as an eligibility criterion. </p> <section id="CD013143-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013143-list-0004"> <li> <p>Urologic symptom scores (continuous outcome)</p> </li> <li> <p>Quality of life (continuous outcome)</p> </li> <li> <p>Major adverse events (dichotomous outcome)</p> </li> </ul> </p> </section> <section id="CD013143-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013143-list-0005"> <li> <p>Retreatment (dichotomous outcome)</p> </li> <li> <p>Erectile function (continuous outcome)</p> </li> <li> <p>Ejaculatory function (continuous outcome)</p> </li> <li> <p>Minor adverse events (dichotomous outcome)</p> </li> <li> <p>Acute urinary retention (dichotomous outcome)</p> </li> <li> <p>Indwelling urinary catheter (continuous outcome)</p> </li> <li> <p>Hospital stay (continuous outcome)</p> </li> </ul> </p> <section id="CD013143-sec-0050"> <h6 class="title">Method and timing of outcome measurement</h6> <p>We considered the clinically important differences for the review outcome measures to rate the overall certainty of evidence in <a href="./full#CD013143-tbl-0001">summary of findings Table for the main comparison</a> (<a href="./references#CD013143-bbs2-0037" title="JaeschkeR , SingerJ , GuyattGH . Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials1989;10(4):407‐15. [PUBMED: 2691207] ">Jaeschke 1989</a>; <a href="./references#CD013143-bbs2-0038" title="JohnstonBC , PatrickDL , BusseJW , SchunemannHJ , AgarwalA , GuyattGH . Patient‐reported outcomes in meta‐analyses‐‐Part 1: assessing risk of bias and combining outcomes. Health and Quality of Life Outcomes2013;11:109. [PUBMED: 23815754] ">Johnston 2013</a>). </p> <section id="CD013143-sec-0051"> <p><b>Urologic symptom scores</b></p> <p> <ul id="CD013143-list-0006"> <li> <p>Mean change from baseline or final mean value, measured using a validated scale (such as IPSS) </p> </li> <li> <p>We considered the improvement of an IPSS score of three points as the minimal clinically important difference (MCID) to assess efficacy and comparative effectiveness (<a href="./references#CD013143-bbs2-0008" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. [PUBMED: 7563343] ">Barry 1995</a>). If possible, we used different thresholds of MCID based on the severity of IPSS, with a threshold of three points for men with mild LUTS, five for moderate LUTS, and eight for severe LUTS (<a href="./references#CD013143-bbs2-0008" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. [PUBMED: 7563343] ">Barry 1995</a>). </p> </li> </ul> </p> </section> <section id="CD013143-sec-0052"> <p><b>Quality of life</b></p> <p> <ul id="CD013143-list-0007"> <li> <p>Mean change from baseline or final mean value measured as a validated scale (such as IPSS‐quality of life or BPH Impact index) </p> </li> <li> <p>We used a MCID of 0.5 to assess efficacy and comparative effectiveness (<a href="./references#CD013143-bbs2-0058" title="ReesJ . Patients not P values. BJU International2015; Vol. 115, issue 5:678‐9. [PUBMED: 25885560] ">Rees 2015</a>). A BPH Impact Index score of one as an MCID was used to indicate improvement (<a href="./references#CD013143-bbs2-0010" title="BarryMJ , CantorA , RoehrbornCG , CAMUS Study Group. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. Journal of Urology2013;189(3):987‐92. [PUBMED: 23017510] ">Barry 2013</a>). </p> </li> </ul> </p> </section> <section id="CD013143-sec-0053"> <p><b>Major adverse events</b></p> <p> <ul id="CD013143-list-0008"> <li> <p>Example: postoperative haemorrhage requiring admission or intervention</p> </li> <li> <p>We used the Clavien‐Dindo classification system to assess surgical complications (<a href="./references#CD013143-bbs2-0017" title="DindoD , DemartinesN , ClavienPA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery2004;240(2):205‐13. [PUBMED: 15273542] ">Dindo 2004</a>), and categorised grade III, IV and V complications as major adverse events (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). If the study authors of eligible studies did not use the Clavien‐Dindo system, we judged the adverse events by severity using the available information described in the studies. </p> </li> </ul> </p> </section> <section id="CD013143-sec-0054"> <p><b>Retreatment</b></p> <p> <ul id="CD013143-list-0009"> <li> <p>Events requiring other surgical treatment modalities (e.g. TURP) after intervention</p> </li> </ul> </p> </section> <section id="CD013143-sec-0055"> <p><b>Erectile function</b></p> <p> <ul id="CD013143-list-0010"> <li> <p>Mean change from baseline or final mean value measured as total score on the International Index of Erectile Function (IIEF)‐5 questionnaire, also known as Sexual Health Inventory for Men (<a href="./references#CD013143-bbs2-0064" title="RosenRC , RileyA , WagnerG , OsterlohIH , KirkpatrickJ , MishraA . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology1997;49(6):822‐30. [PUBMED: 9187685] ">Rosen 1997</a>) </p> </li> <li> <p>We considered the MCID an erectile function domain score of four on the IIEF (<a href="./references#CD013143-bbs2-0067" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010‐6. [PUBMED: 21855209] ">Rosen 2011</a>). If possible, we used different thresholds of MCID based on the severity of erectile dysfunction, with a threshold of two for men with mild erectile dysfunction, five for moderate erectile dysfunction, and seven for men with severe erectile dysfunction (<a href="./references#CD013143-bbs2-0067" title="RosenRC , AllenKR , NiX , AraujoAB . Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. European Urology2011;60(5):1010‐6. [PUBMED: 21855209] ">Rosen 2011</a>). We considered a difference in IIEF‐5 score of over five points as the MCID (<a href="./references#CD013143-bbs2-0072" title="SpalivieroM , StromKH , GuX , ArakiM , CulkinDJ , WongC . Does Greenlight HPS(™) laser photoselective vaporization prostatectomy affect sexual function?. Journal of Endourology2010;24(12):2051‐7. [PUBMED: 20964486] ">Spaliviero 2010</a>). </p> </li> </ul> </p> </section> <section id="CD013143-sec-0056"> <p><b>Ejaculatory function</b></p> <p> <ul id="CD013143-list-0011"> <li> <p>Mean change from baseline or final mean value measured using the Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ‐EjD) or the four‐item version of the MSHQ‐EjD (<a href="./references#CD013143-bbs2-0065" title="RosenRC , CataniaJ , PollackL , AlthofS , O'LearyM , SeftelAD . Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology2004;64(4):777‐82. [PUBMED: 15491719] ">Rosen 2004</a>; <a href="./references#CD013143-bbs2-0066" title="RosenRC , CataniaJA , AlthofSE , PollackLM , O'LearyM , SeftelAD , et al. Development and validation of four‐item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology2007;69(5):805‐9. [PUBMED: 17482908] ">Rosen 2007</a>) </p> </li> <li> <p>We considered the MCID as an ejaculatory function domain score of two on the MSHQ or four‐item version of the MSHQ‐EjD (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>; <a href="./references#CD013143-bbs2-0065" title="RosenRC , CataniaJ , PollackL , AlthofS , O'LearyM , SeftelAD . Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology2004;64(4):777‐82. [PUBMED: 15491719] ">Rosen 2004</a>; <a href="./references#CD013143-bbs2-0066" title="RosenRC , CataniaJA , AlthofSE , PollackLM , O'LearyM , SeftelAD , et al. Development and validation of four‐item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology2007;69(5):805‐9. [PUBMED: 17482908] ">Rosen 2007</a>) </p> </li> </ul> </p> <p><b>Minor adverse events</b> </p> <p> <ul id="CD013143-list-0012"> <li> <p>Example: postoperative fever or pain requiring medication</p> </li> <li> <p>We used the Clavien‐Dindo classification system to assess surgical complications (<a href="./references#CD013143-bbs2-0017" title="DindoD , DemartinesN , ClavienPA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery2004;240(2):205‐13. [PUBMED: 15273542] ">Dindo 2004</a>), and categorised grade I and II complications as minor adverse events (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). If the authors of eligible studies did not use the Clavien‐Dindo system, we judged the severity of adverse events using the available information described in these studies. </p> </li> </ul> </p> </section> <section id="CD013143-sec-0057"> <p><b>Acute urinary retention</b></p> <p> <ul id="CD013143-list-0013"> <li> <p>Events requiring catheterization after the intervention</p> </li> </ul> </p> </section> <section id="CD013143-sec-0058"> <p><b>Indwelling urinary catheter</b></p> <p> <ul id="CD013143-list-0014"> <li> <p>Measured in hours from intervention to urinary catheter removal</p> </li> </ul> </p> </section> <section id="CD013143-sec-0059"> <p><b>Hospital stay</b></p> <p> <ul id="CD013143-list-0015"> <li> <p>Measured in days from admission to discharge</p> </li> </ul> </p> <p>There were no reported thresholds in adverse events, retreatment, acute urinary retention, indwelling urinary catheter, and hospital stay. We considered the clinically important differences for adverse events, retreatment, acute urinary retention, and indwelling catheter as relative risk reductions of at least 25% (<a href="./references#CD013143-bbs2-0028" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011a</a>). We used a MCID of one day (24 hours) to assess efficacy and comparative effectiveness for indwelling urinary catheter and hospital stay. </p> <p>We considered outcomes measured up to and including 12 months after randomisation as short‐term, and later than 12 months as long‐term, for urologic symptom scores, quality of life, major adverse events, retreatment, erectile function, ejaculatory function, minor adverse events, and acute urinary retention. We assessed retreatment, indwelling urinary catheter and hospital stay as short‐term only. </p> </section> </section> <section id="CD013143-sec-0060"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p>We have presented a 'Summary of findings' table that reports on the following outcomes (listed according to priority). </p> <p> <ul id="CD013143-list-0016"> <li> <p>Urologic symptom scores</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Major adverse events</p> </li> <li> <p>Retreatment</p> </li> <li> <p>Erectile function</p> </li> <li> <p>Ejaculatory function</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD013143-sec-0061"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search with no restrictions on the language or status of publication. We plan to rerun searches within three months prior to the anticipated publication of this review. </p> <section id="CD013143-sec-0062"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources, from the inception of each database (<a href="./appendices#CD013143-sec-0141">Appendix 1</a>). The date of last search of all databases was 11 February 2019. </p> <p> <ul id="CD013143-list-0017"> <li> <p>Cochrane Library via Wiley</p> <ul id="CD013143-list-0018"> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR, 2019, Issue 1) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 1)</p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE)</p> </li> <li> <p>Health Technology Assessment Database (HTA)</p> </li> </ul> </li> <li> <p>MEDLINE via Ovid (from 1946 to February 2019)</p> </li> <li> <p>Embase via Elsevier (from 1974 to February 2019)</p> </li> <li> <p>Scopus (from 1966 to February 2019)</p> </li> <li> <p>Web of Science (from 1900 to February 2019)</p> </li> <li> <p>LILACS (Latin American and the Caribbean Health Sciences Literature, <a href="http://www.bireme.br/" target="_blank">www.bireme.br/</a>, from 1982 to February 2019) </p> </li> </ul> </p> <p>We also searched the following.</p> <p> <ul id="CD013143-list-0019"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) </p> </li> <li> <p>Grey literature repository from the current Grey Literature Report (<a href="http://www.greylit.org/" target="_blank">www.greylit.org/</a>) </p> </li> </ul> </p> <p>If we detected additional relevant key words during any of the electric or other searches, we modified the electronic search strategies to incorporate these terms and documented the changes. </p> </section> <section id="CD013143-sec-0063"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible studies or ancillary publications by searching the reference lists of included studies, reviews, meta‐analyses and health technology assessment reports. We also contacted the authors of included studies to identify any further studies that we may have missed. We contacted drug/device manufacturers for ongoing or unpublished studies. We searched only the published abstract proceedings of relevant meetings of the American Urological Association, European Association of Urology, and International Continence Society for the last three years (2016 to 2018) for unpublished studies. </p> </section> </section> <section id="CD013143-sec-0064"> <h3 class="title" id="CD013143-sec-0064">Data collection and analysis</h3> <section id="CD013143-sec-0065"> <h4 class="title">Selection of studies</h4> <p>We used <a href="./references#CD013143-bbs2-0021" title="Clarivate Analytics. EndNote. Version 7.5. Clarivate Analytics, 2016. ">Endnote</a> 2016 reference management software to identify and remove potential duplicate records. Two review authors independently scanned abstracts and titles to determine which studies should be assessed further using <a href="./references#CD013143-bbs2-0014" title="Veritas Health Innovation. Covidence. Version accessed 16 August 2017. Melbourne, Australia: Veritas Health Innovation, 2013. ">Covidence 2017</a> software. Two review authors categorised all potentially relevant records as full text or mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013143-bbs2-0033" title="HigginsJP , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreements between the two authors through consensus or recourse to a third review author (PD). If a resolution was not possible, we designated the corresponding study as 'awaiting classification', and we documented reasons for the exclusion of studies in the <a href="./references#CD013143-sec-0152" title="">Characteristics of excluded studies</a> table. We presented an adapted PRISMA flow diagram showing the process of study selection (<a href="./references#CD013143-bbs2-0047" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS medicine2009;6(7):e1000100. [PUBMED: 19621070] ">Liberati 2009</a>). </p> </section> <section id="CD013143-sec-0066"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data extraction form that we pilot tested ahead of time.</p> <p>For studies that fulfilled our inclusion criteria, two review authors independently abstracted the following information, which we provide in the <a href="./references#CD013143-sec-0151" title="">Characteristics of included studies</a> table. </p> <p> <ul id="CD013143-list-0020"> <li> <p>Study design</p> </li> <li> <p>Study dates ( if dates were not available then this was reported as such)</p> </li> <li> <p>Study settings and country</p> </li> <li> <p>Participant inclusion and exclusion criteria (e.g. age, baseline IPSS, medical pretreatment)</p> </li> <li> <p>Participant details, baseline demographics (e.g. age, prostate size, IPSS)</p> </li> <li> <p>The number of participants by study and by study arm</p> </li> <li> <p>Details of relevant experimental intervention, such as delivery devices (e.g. size of cystoscope) for Aquablation and comparator intervention (e.g. monopolar versus bipolar energy, type of laser) </p> </li> <li> <p>Definitions of relevant outcomes, and method (e.g. type of instrument, such as IPSS) and timing of outcome measurement (e.g. in months) as well as any relevant subgroups (e.g. based on age, prostate volume, severity of LUTS) </p> </li> <li> <p>Study funding sources</p> </li> <li> <p>Declarations of interest by primary investigators</p> </li> </ul> </p> <p>We extracted outcome data relevant to this Cochrane Review as needed for the calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals for the study population in a 2 x 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations or other data necessary to calculate this information. </p> <p>We resolved any disagreements by discussion, or, if required, by consultation with a third review author (PD). </p> <p>We have provided information, including study identifiers, about potentially relevant ongoing studies in the Characteristics of ongoing studies table. </p> <p>We contacted the authors of included studies to obtain key missing data as needed.</p> <section id="CD013143-sec-0067"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports relating to a primary study, we maximised the yield of information by mapping all publications to unique studies and collating all available data. We used the most complete data set aggregated across all known publications. In case of doubt, we gave priority to publications reporting the longest follow‐ups associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD013143-sec-0068"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ECH and JHJ) independently assessed the risk of bias of each included study. We resolved disagreements by consensus, or by consultation with a third review author (PD). We have presented a 'Risk of bias' summary figure to illustrate these findings. We further summarised the risk of bias across the studies and domains for each outcome in each included study in accordance with the approach for the summary assessments of the risk of bias presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013143-bbs2-0034" title="HigginsJPT , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017a</a>). </p> <section id="CD013143-sec-0069"> <h5 class="title">Assessment of risk of bias in RCTs</h5> <p>We assessed risk of bias using Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD013143-bbs2-0034" title="HigginsJPT , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017a</a>). We assessed the following domains. </p> <p> <ul id="CD013143-list-0021"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>We judged 'Risk of bias' domains as 'low risk', 'high risk' or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013143-bbs2-0034" title="HigginsJPT , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017a</a>). </p> <p>For selection bias (random sequence generation and allocation concealment), we evaluated risk of bias at study level. </p> <p>For performance bias (blinding of participants and personnel), we considered all outcomes similarly susceptible to performance bias. </p> <p>For detection bias (blinding of outcome assessment), we grouped outcomes as susceptible to detection bias (subjective) or not susceptible to detection bias (objective). </p> <p>We defined the following outcomes as subjective outcomes.</p> <p> <ul id="CD013143-list-0022"> <li> <p>Urologic symptom scores</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Erectile function</p> </li> <li> <p>Ejaculatory function</p> </li> <li> <p>Minor adverse events</p> </li> </ul> </p> <p>We defined the following outcomes as objective outcomes.</p> <p> <ul id="CD013143-list-0023"> <li> <p>Major adverse events</p> </li> <li> <p>Retreatment</p> </li> <li> <p>Acute urinary retention</p> </li> <li> <p>Indwelling urinary catheter</p> </li> <li> <p>Hospital stay</p> </li> </ul> </p> <p>We also assessed attrition bias (incomplete outcome data) on an outcome‐specific basis and presented the judgment for each outcome separately when reporting our findings in the 'Risk of bias' tables. </p> <p>For reporting bias (selective reporting), we evaluated risk of bias at study level.</p> </section> <section id="CD013143-sec-0070"> <h5 class="title">Assessment of risk of bias in non‐RCTs</h5> <p>We could not find any non‐RCTs with concurrent comparison groups. However, if we had included non‐RCTs, we would have used ROBINS‐I for assessing risk of bias in non‐RCTs (<a href="./references#CD013143-bbs2-0073" title="SterneJA , HernanMA , ReevesBC , SavovicJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016;355:i4919. [PUBMED: 27733354] ">Sterne 2016a</a>; <a href="./references#CD013143-bbs2-0074" title="SterneJA , HigginsJP , ElbersRG , Reeves BC and the development group for ROBINS‐I. Risk of bias in non‐randomized studies of interventions (ROBINS‐I): detailed guidance, updated 12 October 2016. Available from www.riskofbias.info (accessed 6 July 2018). ">Sterne 2016b</a>). We would have assessed the following domains. </p> <p> <ul id="CD013143-list-0024"> <li> <p>Bias due to confounding</p> </li> <li> <p>Bias in selection of participants into the study</p> </li> <li> <p>Bias in classification of interventions</p> </li> <li> <p>Bias due to deviations from intended interventions</p> </li> <li> <p>Bias due to missing data</p> </li> <li> <p>Bias in measurement of outcomes</p> </li> <li> <p>Bias in selection of the reported result</p> </li> </ul> </p> <p>We would have judged 'Risk of bias' domains as 'low risk', 'moderate risk', 'serious risk', 'critical risk', or 'no information' and would have evaluated individual bias items as described in <a href="./references#CD013143-bbs2-0073" title="SterneJA , HernanMA , ReevesBC , SavovicJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016;355:i4919. [PUBMED: 27733354] ">Sterne 2016a</a> and <a href="./references#CD013143-bbs2-0074" title="SterneJA , HigginsJP , ElbersRG , Reeves BC and the development group for ROBINS‐I. Risk of bias in non‐randomized studies of interventions (ROBINS‐I): detailed guidance, updated 12 October 2016. Available from www.riskofbias.info (accessed 6 July 2018). ">Sterne 2016b</a>. </p> <p><b>Confounding factors</b> </p> <p>We would have considered the following factors as sources of baseline confounding. We would have not considered time‐varying confounding as this is not relevant in this setting (<a href="./references#CD013143-bbs2-0074" title="SterneJA , HigginsJP , ElbersRG , Reeves BC and the development group for ROBINS‐I. Risk of bias in non‐randomized studies of interventions (ROBINS‐I): detailed guidance, updated 12 October 2016. Available from www.riskofbias.info (accessed 6 July 2018). ">Sterne 2016b</a>) </p> <p> <ul id="CD013143-list-0025"> <li> <p>Age</p> </li> <li> <p>Major comorbidities such as pre‐existing cardiovascular disease</p> </li> <li> <p>Prostate size</p> </li> <li> <p>Baseline questionnaire score (such as IPSS, IPSS‐quality of life, IIEF‐5, MSHQ‐EjD)</p> </li> </ul> </p> </section> </section> <section id="CD013143-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs, unless different studies used different measures to assess the same outcome, in which case we re‐expressed the data as standardised mean differences (SMDs) with 95% CIs. </p> </section> <section id="CD013143-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was each individual participant. We planned to take into account the level at which randomisation occurred, such as cluster‐randomised trials, and the multiple observations of the same outcome. If more than one comparison from the same study was eligible for inclusion in the same meta‐analysis, we either combined study groups to create a single pairwise comparison or appropriately reduced the sample size so that the same participants did not contribute multiple times (if possible, splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlations arising from the same set of participants being in multiple comparisons (<a href="./references#CD013143-bbs2-0016" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors),Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handboo. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD013143-sec-0073"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from corresponding study authors, if feasible, and performed intention‐to‐treat analyses if data were available. Otherwise, we performed available case analyses. We investigated attrition rates (e.g. dropouts, losses to follow‐ups and withdrawals), and the critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD013143-sec-0074"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity. However, we included only one RCT and, therefore, we could not assess heterogeneity. If we had included at least two studies, we would have identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and by using the I<sup>2</sup> statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD013143-bbs2-0031" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [PUBMED: 12111919] ">Higgins 2002</a>; <a href="./references#CD013143-bbs2-0032" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [PUBMED: 12958120] ">Higgins 2003</a>). We would have interpreted the I<sup>2</sup> statistic as follows (<a href="./references#CD013143-bbs2-0016" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors),Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handboo. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> <p> <ul id="CD013143-list-0026"> <li> <p>0% to 40%: may not be important</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>If we had identified heterogeneity, we would have attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD013143-sec-0075"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to obtain study protocols to assess selective outcome reporting.</p> <p>As we included only one study, we could not use funnel plots to assess small study effects. If we had included 10 or more studies in a meta‐analysis, we would have used funnel plots to assess small study effects (<a href="./references#CD013143-bbs2-0075" title="SterneJA , EggerM , MoherD , BoutronI (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J,Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to study size, poor methodological design (and hence bias of small studies) and publication bias. Therefore, we would have interpreted results carefully. </p> </section> <section id="CD013143-sec-0076"> <h4 class="title">Data synthesis</h4> <p>As we included only one RCT, we only re‐analysed and reported single study data using Review Manager 5 software (<a href="./references#CD013143-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) in accordance with the guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013143-bbs2-0016" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors),Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handboo. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD013143-sec-0077"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity and carried out subgroup analyses with the investigation of interactions. </p> <p> <ul id="CD013143-list-0027"> <li> <p>Patient age (less than 65 years versus 65 years or more)</p> </li> <li> <p>Prostate volume (less than 50 mL versus 50 mL or more)</p> </li> <li> <p>Severity of LUTS based on IPSS (score less than or equal to 19 (moderately symptomatic) versus greater than 19 (severely symptomatic)) </p> </li> </ul> </p> <p>These subgroup analyses are based on the following observations.</p> <p> <ul id="CD013143-list-0028"> <li> <p>Age is a well‐known risk factor of BPH surgery. Older patients have a higher rate of postoperative complications compared with younger patients (<a href="./references#CD013143-bbs2-0011" title="BhojaniN , GandagliaG , SoodA , RaiA , PucherilD , ChangSL , et al. Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. Journal of Endourology2014;28(7):831‐40. [PUBMED: 24517323] ">Bhojani 2014</a>; <a href="./references#CD013143-bbs2-0056" title="PariserJJ , PearceSM , PatelSG , BalesGT . National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology2015;86(4):721‐5. [PUBMED: 26276574] ">Pariser 2015</a>). The age cut‐off is based on the World Health Organization (WHO) definition of old age (<a href="./references#CD013143-bbs2-0077" title="World Health Organization. Proposed working definition of an older person in Africa for the MDS project. www.who.int/healthinfo/survey/ageingdefnolder/en (accessed 1 March 2018). ">WHO 2012</a>). </p> </li> <li> <p>The outcomes and complications of minimally invasive procedures, such as TURP, correlate with prostate volume (<a href="./references#CD013143-bbs2-0059" title="ReichO , GratzkeC , BachmannA , SeitzM , SchlenkerB , HermanekP , et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. Journal of Urology2008;180(1):246‐9. [PUBMED: 18499179] ">Reich 2008</a>). We adjusted the prostate volume of 40 mL, which we selected as a threshold on our protocol (<a href="./references#CD013143-bbs2-0079" title="HwangEC , JungJH , BorofskyM , KimMH , DahmP . Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2018, Issue 10. [DOI: 10.1002/14651858.CD013143] ">Hwang 2018</a>), to 50 mL based on the available evidence (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). </p> </li> <li> <p>The relationship between changes in IPSS scores and patient global ratings of improvement is influenced by the baseline scores (<a href="./references#CD013143-bbs2-0008" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker‐CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. Journal of Urology1995;154(5):1770‐4. [PUBMED: 7563343] ">Barry 1995</a>). </p> </li> </ul> </p> <p>We planned to limit subgroup analyses to the primary outcomes only.</p> </section> <section id="CD013143-sec-0078"> <h4 class="title">Sensitivity analysis</h4> <p>We only identified one RCT and were, therefore, not able to perform sensitivity analyses. If we had performed sensitivity analysis, we would have limited this to the primary outcomes, in order to explore the influence of the following (when applicable) on effect sizes. </p> <p> <ul id="CD013143-list-0029"> <li> <p>Restricting the analysis in RCTs by taking into account risk of bias, by excluding studies at 'high risk' or 'unclear risk </p> </li> </ul> </p> <section id="CD013143-sec-0079"> <h5 class="title">'Summary of findings' table</h5> <p>We presented the overall certainty of evidence for each outcome, according to the GRADE approach (<a href="./references#CD013143-bbs2-0027" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchunemannHJ . What is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. [PUBMED: 18456631] '>Guyatt 2008</a>)<i>.</i> For each comparison, two review authors (ECH and JHJ) independently rated the certainty of evidence for each outcome as 'high', 'moderate', 'low', or 'very low' using the GRADEpro Guideline Development Tool (<a href="./references#CD013143-bbs2-0026" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 13 December 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>). We resolved any discrepancies by consensus, or, if needed, by arbitration by a third review author (PD). For each comparison, we presented a summary of the evidence for the main outcomes in the 'Summary of findings' table, which provides key information about the best estimate of the magnitude of effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence of effect estimates for each outcome (<a href="./references#CD013143-bbs2-0029" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011b</a>; <a href="./references#CD013143-bbs2-0070" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017a</a>). </p> <p>For RCTs, we considered five criteria, not only related to internal validity (risk of bias, inconsistency, imprecision, and publication bias), but also to external validity (directness of results), for downgrading the certainty of evidence for a specific outcome (<a href="./references#CD013143-bbs2-0071" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017b</a>). For non‐RCTs, we planned to consider five criteria for downgrading the certainty of evidence, followed by three criteria for upgrading the certainty of evidence (large magnitude of effects, all plausible confounding that would reduce a demonstrated effect or suggest a spurious effect when results show no effect, and dose‐response gradient; <a href="./references#CD013143-bbs2-0030" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011c</a>). </p> <p>However, we could not find any non‐RCTs. Please refer to the <a href="#CD013143-sec-0047">Types of outcome measures</a> for the outcomes included in <a href="./full#CD013143-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013143-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013143-sec-0080"></div> <section id="CD013143-sec-0081"> <h3 class="title">Description of studies</h3> <section id="CD013143-sec-0082"> <h4 class="title">Results of the search</h4> <p>We identified 152 records through searching electronic databases and 20 records in trials registers. We found no applicable records in the grey literature repository. After the removal of duplicates, we screened the titles and abstracts of the remaining 134 records, of which we excluded 111. Only one study, reported in 17 records, ultimately met the inclusion criteria for the assessment of the review question (for details, refer to <a href="#CD013143-fig-0002">Figure 2</a>). There were no ongoing studies that met the inclusion criteria, or were relevant to the review question. </p> <div class="figure" id="CD013143-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013143-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013143-sec-0083"> <h4 class="title">Included studies</h4> <p>We identified one RCT (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). For details, please refer to the <a href="./references#CD013143-sec-0151" title="">Characteristics of included studies</a> table, <a href="#CD013143-tbl-0002">Table 1</a> and <a href="#CD013143-tbl-0003">Table 2</a>. The included study compared Aquablation with transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH). Altogether, 275 participants were screened for enrolment in 17 sites in four countries (Australia, New Zealand, the UK and the USA). Between October 2015 and December 2016, <a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a> randomly assigned 184 participants. Nineteen surgeons were involved in this study. </p> <div class="table" id="CD013143-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study name</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study period (year to year)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting/Country</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description of participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of follow‐up</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IPSS</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prostate volume</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] "><b>Gilling 2018</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>October 2015‐December 2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Multicenter (17 centres)/multicountry (Australia, New Zealand, UK, USA)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>LUTS due to BPH in men 45‐80 years of age with a prostate size between 30 and 80 mL (measured with transrectal ultrasound), IPSS ≥ 12, Q<sub>max</sub> &lt; 15mL/s </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aquablation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.0 ± 7.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9 ± 6.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.1 ± 16.2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TURP (monopolar 36 (55.4%), bipolar 29 (44.6%))</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8 ± 7.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.2 ± 6.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.8 ± 13.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>BPH:</b> benign prostatic hyperplasia; <b>IPSS:</b> International Prostate Symptom Score; <b>LUTS:</b> low urinary tract symptoms; <b>Q<sub>max</sub>:</b> maximum flow rate; <b>TURP:</b> transurethral resection of prostate </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013143-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Screened/eligible (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomised (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed (N): efficacy<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed (N): safety<sup>b</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Finishing study (N (%))</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] "><b>Gilling 2018</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aquablation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>275/184</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 (98.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TURP monopolar (36 (55.4%), bipolar 29 (44.6%))</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (92.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>184</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>174</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>181</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>177</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TURP:</b> transurethral resection of prostate </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The number of participants analysed for urologic symptom scores.<br/> <sup>b</sup>The number of participants with adverse events. </p> </div> </div> <section id="CD013143-sec-0084"> <h5 class="title">Source of data</h5> <p>We identified two published full‐text records, the first record being an overall analysis and the second record being a pre‐planned subgroup analysis of the same study. We contacted the corresponding author of the included study to get additional information and received a reply (<a href="./appendices#CD013143-sec-0142">Appendix 2</a>). </p> </section> <section id="CD013143-sec-0085"> <h5 class="title">Participants</h5> <p>We included 184 randomised participants (Aquablation n = 117; TURP n = 67), of whom 174 were included in the efficacy analysis (Aquablation n = 114; TURP n = 60) and 181 were included in the safety analysis (Aquablation n = 116; TURP n = 65). We have reported the baseline characteristics in <a href="./references#CD013143-sec-0151" title="">Characteristics of included studies</a>. </p> </section> <section id="CD013143-sec-0086"> <h5 class="title">Intervention and comparator</h5> <p>The study used Aquablation, which was performed using the AquaBeam System (<a href="./references#CD013143-bbs2-0057" title="PROCEPT BioRobotics, Redwood Shores, California, USA. www.procept‐biorobotics.com. ">PROCEPT BioRobotics</a>), as an intervention and used TURP as a comparator. The follow‐up duration was 12 months. </p> </section> <section id="CD013143-sec-0087"> <h5 class="title">Comparisons</h5> <p>No study compared Aquablation to laser ablation of the prostate, laser enucleation of the prostate, other minimally invasive therapies, or simple prostatectomy. We did not find any non‐RCTs with concurrent comparison groups that met our review’s inclusion criteria. </p> </section> <section id="CD013143-sec-0088"> <h5 class="title">Outcomes</h5> <p>We identified reporting of all primary outcomes in the included study for this comparison (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). In addition, <a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a> reported all our secondary outcomes, except for the duration of indwelling urinary catheter usage. </p> </section> <section id="CD013143-sec-0089"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>This study was supported by the company that produced the Aquablation device. This study’s authors also have financial relationships with the same company. </p> </section> </section> <section id="CD013143-sec-0090"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies (6 records) out of three studies (23 records) after evaluation of the full‐text publications. These studies had no comparator, that is, they were single‐armed studies (<a href="./references#CD013143-bbs2-0002" title="BachT , GiannakisI , BachmannA , FioriC , Gomez‐SanchaF , HerrmannTR , et al. Aquablation of the prostate: single‑center results of a non‑selected, consecutive patient cohort. World Journal of Urology 2018 Oct 4 [Epub ahead of print]. [DOI: 10.1007/s00345‐018‐2509‐y] ">Bach 2018</a>; <a href="./references#CD013143-bbs2-0003" title="Waterjet ablation therapy for endoscopic resection of prostate tissue II (WATERII). clinicaltrials.gov/ct2/show/NCT03123250. BhojaniN , NguyenDD , KaufmanRPJr , EltermanD , ZornKC . Comparison of &lt; 100 cc prostates and &gt; 100 cc prostates undergoing Aquablation for benign prostatic hyperplasia. World Journal of Urology 2018 Oct 28 [Epub ahead of print]. [DOI: 10.1007/s00345‐018‐2535‐9] DesaiM , BidairM , BhojaniN , TrainerA , ArtherA , KramolowskyE , et al. WATER II (80‐150 mL) procedural outcomes. BJU International2019;123(1):106‐12. [DOI: 10.1111/bju.14360] DesaiM , BidairM , ZornKC , TrainerA , ArtherA , KramolowskyE , et al. Aquablation for BPH in Large Prostates (80‐150cc): 6‐Month Results From the WATER II Trial. BJU international 2019 Feb 8 [Epub ahead of print]. [DOI: 10.1111/bju.14703] ZornKC , GoldenbergSL , PatersonR , SoA , EltermanD , BhojaniN . Aquablation among novice users in Canada: a WATER II subpopulation analysis. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada 2018 Oct 15 [Epub ahead of print]. [DOI: 10.5489/cuaj.5501] ">Desai 2019</a>). Please refer to <a href="./references#CD013143-sec-0152" title="">Characteristics of excluded studies</a> table. </p> <section id="CD013143-sec-0091"> <h5 class="title">Studies awaiting classification and ongoing studies</h5> <p>There were no studies awaiting classification or ongoing studies.</p> </section> </section> </section> <section id="CD013143-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>For details, please refer to <a href="./references#CD013143-sec-0151" title="">Characteristics of included studies</a> section, the 'Risk of bias' table, <a href="./full#CD013143-tbl-0001">summary of findings Table for the main comparison</a> for the main comparison, <a href="#CD013143-fig-0003">Figure 3</a> and <a href="#CD013143-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD013143-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013143-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD013143-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD013143-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD013143-sec-0093"> <h4 class="title">Allocation</h4> <p>Random sequence generation and allocation concealment were performed adequately, and we judged this study to be at low risk of selection bias. </p> </section> <section id="CD013143-sec-0094"> <h4 class="title">Blinding</h4> <section id="CD013143-sec-0095"> <h5 class="title">Performance bias</h5> <p>Participants were blinded, but personnel (surgeons) were not blinded. We, therefore, rated the risk of bias as high. </p> </section> <section id="CD013143-sec-0096"> <h5 class="title">Detection bias</h5> <section id="CD013143-sec-0097"> <h6 class="title">Susceptible (subjective) outcomes</h6> <p>These were urologic symptom scores, quality of life, erectile function, ejaculatory function, and minor adverse events. </p> <p><a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a> reported that the assessors of these outcomes were blinded. We rated the risk of bias for these outcomes as low. </p> </section> <section id="CD013143-sec-0098"> <h6 class="title">Not susceptible (objective) outcomes</h6> <p>These were major adverse events, retreatment, acute urinary retention, indwelling urinary catheter usage, and hospital stay. </p> <p>Blinding of outcome assessors is not relevant to these outcomes. We rated the risk of bias for these outcomes as low. </p> </section> </section> </section> <section id="CD013143-sec-0099"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a> measured erectile and ejaculatory function in a limited subset of participants who were sexually active at baseline and sexually active during the follow‐up period. We judged the risk of attrition bias as high for these outcomes. </p> <p>Attrition was less than 10% in both the Aquablation and TURP groups for other outcomes. We judged the risk of attrition bias as low for these outcomes. </p> </section> <section id="CD013143-sec-0100"> <h4 class="title">Selective reporting</h4> <p>A protocol was available and the reported outcomes and their analyses in the included study corresponded to how these had been planned. However, secondary outcomes were not pre‐specified in the ClinicalTrials.gov registry (NCT02505919) and several quality‐of‐life measurement were not reported (e.g. EuroQOL‐5D). We therefore, assigned a judgment of unclear risk of reporting bias to these secondary outcomes. </p> </section> <section id="CD013143-sec-0101"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias.</p> </section> </section> <section id="CD013143-sec-0102"> <h3 class="title" id="CD013143-sec-0102">Effects of interventions</h3> <p>See: <a href="./full#CD013143-tbl-0001"><b>Summary of findings for the main comparison</b> Aquablation compared to transurethral resection of the prostate for benign prostatic hyperplasia</a> </p> <p>Please refer to <a href="./references#CD013143-fig-0005" title="">Analysis 1.1</a> to <a href="./references#CD013143-fig-0014" title="">Analysis 1.10</a>, and <a href="./full#CD013143-tbl-0001">summary of findings Table for the main comparison</a>. We also analysed the six‐month results for each outcome in <a href="./references#CD013143-fig-0015" title="">Analysis 2.1</a> to <a href="./references#CD013143-fig-0024" title="">Analysis 2.10</a> but did not describe these below. </p> <section id="CD013143-sec-0103"> <h4 class="title">Aquablation versus transurethral resection of the prostate (TURP)</h4> <section id="CD013143-sec-0104"> <h5 class="title">Primary outcomes</h5> <section id="CD013143-sec-0105"> <h6 class="title">Urologic symptom scores (assessed with: IPSS)</h6> <p>Aquablation likely results in little to no difference in urologic symptom scores compared to TURP (MD −0.06, 95% CI −2.51 to 2.39; participants = 174; studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0005" title="">Analysis 1.1</a>). We judged the certainty of the evidence to be moderate. We downgraded the certainty of the evidence by one level due to study limitations, namely that of performance bias. </p> </section> <section id="CD013143-sec-0106"> <h6 class="title">Quality of life (assessed with: IPSS‐QoL)</h6> <p>Aquablation may result in little to no difference in quality of life (MD 0.27, 95% CI −0.24 to 0.78; participants = 174; studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0006" title="">Analysis 1.2</a>). We judged the certainty of the evidence to be low. We downgraded the certainty of the evidence by two levels due to study limitations, namely performance bias and imprecision, given that the CI crossed the assumed minimally important difference of 0.5. </p> </section> <section id="CD013143-sec-0107"> <h6 class="title">Major adverse events (assessed with: Clavien‐Dindo classification system; Grade III, IV and V complications) </h6> <p>Aquablation may result in little to no difference in major adverse events (RR 0.84, 95% CI 0.31 to 2.26; participants = 181; studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0007" title="">Analysis 1.3</a>), but we are very uncertain of this finding. This corresponds to 15 fewer major adverse events per 1000 participants (95% CI 64 fewer to 116 more). We judged the certainty of the evidence to be very low. We downgraded the certainty of the evidence by one level due to study limitations, namely performance bias, and by two levels for imprecision, given that the CI was consistent both with a small reduction in major adverse events as well as an appreciable increase in major adverse events. </p> </section> </section> <section id="CD013143-sec-0108"> <h5 class="title">Secondary outcomes</h5> <section id="CD013143-sec-0109"> <h6 class="title">Retreatment</h6> <p>Aquablation may result in little to no difference in retreatments (RR 1.68, 95% CI 0.18 to 15.83; participants = 181; studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0008" title="">Analysis 1.4</a>), but we are very uncertain of this finding. This corresponds to 10 more retreatments per 1000 participants (95% CI 13 fewer to 228 more). We judged the certainty of the evidence to be very low. We downgraded the certainty of the evidence by one level due to study limitations, namely performance bias, and by two levels for imprecision, given that the CI was consistent with both a small or no reduction as well as an appreciable increase in the number of retreatments. </p> </section> <section id="CD013143-sec-0110"> <h6 class="title">Erectile function (assessed with: IIEF‐EF domain)</h6> <p>Aquablation may result in little to no difference in erectile function (MD 2.31, 95% CI −0.63 to 5.25; participants = 64 (sexually active men only); studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0009" title="">Analysis 1.5</a>), but we are very uncertain of this finding. We judged the certainty of the evidence to be very low. We downgraded the certainty of the evidence by two levels for study limitations due to risk of performance and attrition bias, and by one level for imprecision, given that the CI crossed the assumed minimally important difference of 4. </p> </section> <section id="CD013143-sec-0111"> <h6 class="title">Ejaculatory function (assessed with: MSHQ‐EjD)</h6> <p>Aquablation may reduce ejaculatory dysfunction slightly (MD 2.57, 95% CI 0.60 to 4.53; participants = 121 (sexually active men only); studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0010" title="">Analysis 1.6</a>), but we are very uncertain of this finding. We judged the certainty of the evidence to be very low. We downgraded the certainty of the evidence by two levels due to study limitations, namely performance and attrition bias, and by one level for imprecision, given that the CI crossed the assumed minimally important difference of 2. </p> </section> <section id="CD013143-sec-0112"> <h6 class="title">Minor adverse events (assessed with: Clavien‐Dindo classification system; Grade I and II complications) </h6> <p>Aquablation may result in little to no difference in minor adverse events (RR 0.96, 95% CI 0.76 to 1.21; participants = 181; studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0011" title="">Analysis 1.7</a>), but we are very uncertain of this finding. This corresponds to 26 fewer minor adverse events per 1000 participants (95% CI 155 fewer to 136 more). We judged the certainty of the evidence to be very low. We downgraded the certainty of the evidence by one level due to study limitations, namely performance bias, and by two levels for imprecision, based on the assumption that the boundaries of the CI are consistent with both a (large) beneficial effect and undesirable effect. </p> </section> <section id="CD013143-sec-0113"> <h6 class="title">Acute urinary retention</h6> <p>Aquablation may result in little to no difference in acute urinary retention (RR 1.01, 95% CI 0.35 to 2.88; participants = 181; studies = 1; follow‐up time: 12 months; <a href="./references#CD013143-fig-0012" title="">Analysis 1.8</a>), but we are very uncertain of this finding. This corresponds to one more acute urinary retention per 1000 participants (95% CI 50 fewer to 145 more). We judged the certainty of the evidence to be very low. We downgraded the certainty of the evidence by one level due to study limitations, namely performance bias, and by two levels for imprecision, given that the CI is consistent with both a small desirable effect as well as a large undesirable effect. </p> </section> <section id="CD013143-sec-0114"> <h6 class="title">Indwelling urinary catheter</h6> <p>Aquablation likely results in little to no difference in duration of indwelling urinary catheter usage (MD 6.00 hours, 95% CI −9.45 to 21.45; participants = 173; studies = 1; follow‐up time: 3 months; <a href="./references#CD013143-fig-0013" title="">Analysis 1.9</a>). We judged the certainty of the evidence to be moderate. We downgraded the certainty of the evidence by one level due to study limitations, namely performance bias. </p> </section> <section id="CD013143-sec-0115"> <h6 class="title">Hospital stay</h6> <p>Aquablation likely results in little to no difference in hospital stay (MD 0.00 days, 95% CI −0.21 to 0.21; participants = 181; studies = 1; follow‐up time: 3 months; <a href="./references#CD013143-fig-0014" title="">Analysis 1.10</a>). We judged the certainty of the evidence to be moderate. We downgraded the certainty of the evidence by one level due to study limitations, namely performance bias. </p> </section> </section> <section id="CD013143-sec-0116"> <h5 class="title">Subgroup analyses</h5> <p>We performed pre‐planned subgroup analyses (stratified by age, the severity of lower urinary tract symptoms (LUTS) based on International Prostate Symptom Score (IPSS) and prostate volume) with regard to primary outcomes. However, these outcomes come from up to six months' follow‐up. </p> <section id="CD013143-sec-0117"> <h6 class="title">Patient age (under 65 years versus 65 years and older)</h6> <p>For details, please refer to <a href="./references#CD013143-fig-0025" title="">Analysis 3.1</a> to <a href="./references#CD013143-fig-0027" title="">Analysis 3.3</a>. In terms of urologic symptom and quality‐of‐life scores, of the 176 participants, 75 were aged under 65 years (Aquablation n = 49; TURP n = 26), and 101 were aged 65 years old or older (Aquablation n = 65; TURP n = 36). </p> <section id="CD013143-sec-0118"> <p><b>Urologic symptom scores</b></p> <p>For participants aged under 65 years, the MD was −2.40 (95% CI −6.34 to 1.54), and for those aged 65 years or older, the MD was −1.30 (95% CI −4.12 to 1.52). The test for interaction was not significant (P = 0.66, I<sup>2</sup> = 0%). </p> </section> <section id="CD013143-sec-0119"> <p><b>Quality of life</b></p> <p>The MD for quality of life with Aquablation was 0.20 (95% CI −0.52 to 0.92), for participants aged under 65 years and −0.50 (95% CI −1.23 to 0.23), for those aged 65 years or older. The test for interaction was not significant (P = 0.18, I<sup>2</sup> = 44%) </p> </section> <section id="CD013143-sec-0120"> <p><b>Major adverse events</b></p> <p>Of the 181 participants, 77 were under 65 years old (Aquablation n = 50; TURP n = 27), and 104 were 65 years or older (Aquablation n = 66; TURP n = 38). </p> <p>The RR of major adverse events with Aquablation was 6.04 (95% CI 0.35 to 105.26), for participants aged under 65 years, and 0.23 (95% CI 0.05 to 1.13), for those aged 65 years or older. The test for interaction was not significant ( P = 0.05, I<sup>2</sup> = 73.9%). </p> </section> </section> <section id="CD013143-sec-0121"> <h6 class="title">Prostate volume (less than 50 mL versus 50 mL or more)</h6> <p>For details, please refer to <a href="./references#CD013143-fig-0028" title="">Analysis 3.4</a> to <a href="./references#CD013143-fig-0030" title="">Analysis 3.6</a>. In terms of urologic symptom and quality‐of‐life scores, of the 176 participants, 80 had a prostate volume of less than 50 mL (Aquablation n = 51; TURP group n = 29), and 96 had a prostate volume of 50 mL or more (Aquablation n = 63; TURP n = 33). </p> <section id="CD013143-sec-0122"> <p><b>Urologic symptom scores</b></p> <p>For prostate volume of less than 50 mL, the MD was 0.90 (95% CI −2.12 to 3.92), and for prostate volume of 50 mL or more, the MD was −4.10 (95% CI −7.45 to −0.75). The test for interaction was significant (P = 0.03, I<sup>2</sup> = 78.8%). </p> </section> <section id="CD013143-sec-0123"> <p><b>Quality of life</b></p> <p>The MD for quality of life with Aquablation was 0.10 (95% CI −0.61 to 0.81) for prostate volume of less than 50 mL, and −0.50 (95% CI −1.24 to 0.24) for prostate volume of 50 mL or more. The test for interaction was not significant (P = 0.25, I<sup>2</sup> = 23.6%). </p> </section> <section id="CD013143-sec-0124"> <p><b>Major adverse events</b></p> <p>Of the 181 participants, 82 had a prostate volume of less than 50 mL (Aquablation n =52; TURP n = 30), and 99 had a prostate volume of 50 mL or more (Aquablation n = 64; TURP n = 35). </p> <p>The RR of major adverse events with Aquablation was 2.31 (95% CI 0.27 to 19.71), for prostate volume of less than 50 mL, and 0.41 (95% CI 0.10 to 1.73), for prostate volume of 50 mL or more. The test for interaction was not significant (P = 0.19, I<sup>2</sup> = 41.8%). </p> </section> </section> <section id="CD013143-sec-0125"> <h6 class="title">Severity of LUTS based on IPSS (19 or less versus more than 19)</h6> <p>For details, please refer to <a href="./references#CD013143-fig-0031" title="">Analysis 3.7</a> to <a href="./references#CD013143-fig-0033" title="">Analysis 3.9</a>. In terms of urologic symptoms and quality‐of‐life scores, of the 176 participants, 59 had an IPSS of 19 or less (Aquablation n = 36; TURP n = 23), and 117 had an IPSS of more than 19 (Aquablation n = 78; TURP n = 39). </p> <section id="CD013143-sec-0126"> <p><b>Urologic symptom scores</b></p> <p>For IPSS of 19 or less, the MD was −2.70 (95% CI −5.42 to 0.02), and for IPSS of more than 19, the MD was −0.40 (95% CI −2.77 to 1.97). The test for interaction was not significant (P = 0.21, I<sup>2</sup> = 35.9%). </p> </section> <section id="CD013143-sec-0127"> <p><b>Quality of life</b></p> <p>The MD for quality of life with Aquablation was −0.30 (95% CI −1.14 to 0.54), for IPSS of 19 or less, and −0.10 (95% CI −0.77 to 0.57) for IPSS of more than 19. The test for interaction was not significant (P = 0.71, I<sup>2</sup> = 0%). </p> </section> <section id="CD013143-sec-0128"> <p><b>Major adverse events</b></p> <p>Of the 181 participants, 59 had an IPSS of 19 or less (Aquablation n = 36; TURP n = 23), and 122 had an IPSS of more than 19 (Aquablation n = 80; TURP n = 42). </p> <p>The RR of major adverse events with Aquablation was 0.64 (95% CI 0.10 to 4.22), for IPSS of 19 or less, and 0.88 (95% CI 0.22 to 3.48) for IPSS of more than 19. The test for interaction was not significant ( P = 0.79, I<sup>2</sup> = 0%). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013143-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013143-sec-0129"></div> <section id="CD013143-sec-0130"> <h3 class="title" id="CD013143-sec-0130">Summary of main results</h3> <p>Findings of this review are based on a single study with 184 participants, sponsored by the device manufacturer, comparing Aquablation to TURP, that only provided results after short‐term follow‐up of 12 months or less, depending on the outcome. We found no other studies or prospective non‐randomised studies to compare Aquablation to other treatment modalities. </p> <p>Based on this study, Aquablation likely has similar results to TURP for urological symptoms scores and similarly, may improve quality of life. The risk of major adverse events appears to be similar too, but we are very uncertain about this finding. </p> <p>With regard to secondary outcomes, Aquablation may offer similar outcomes in terms of rates of retreatment (up to 12 months), erectile function, minor adverse events, acute urinary retention, indwelling urinary catheter duration and hospital stay. Aquablation may offer a small benefit for sexually active men in terms of ejaculatory function. However, the evidence is very uncertain about the effect of Aquablation on retreatment, erectile and ejaculatory function, minor adverse events and acute urinary retention. </p> <p>Aquablation may improve urologic symptom scores more in participants with a prostate volume of 50 mL or above than in participants with a prostate volume of less than 50 mL. This result should be interpreted with caution because the included study was not designed to assess subgroup effects. We judged the certainty of the evidence for this outcome as low due to study limitations and imprecision. </p> </section> <section id="CD013143-sec-0131"> <h3 class="title" id="CD013143-sec-0131">Overall completeness and applicability of evidence</h3> <p>The following issues deserve consideration when interpreting the results of this review.</p> <p> <ul id="CD013143-list-0030"> <li> <p>The body of evidence stems from a multicenter study sponsored by the device maker. The developmental stages of Aquablation did not follow the IDEAL (Idea, Development, Exploration, Assessment, and Long‐term Study) framework (<a href="./references#CD013143-bbs2-0035" title="HirstA , PhilippouY , BlazebyJ , CampbellB , CampbellM , FeinbergJ , et al. No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations. Annals of Surgery 2018 Apr 24 [Epub ahead of print]. [DOI: 10.1097/SLA.0000000000002794.] ">Hirst 2018</a>). Surgeons performing the procedure likely had specific expertise and experience in this technique. The learning curve for this procedure is not well defined and it is unclear how the results will translate to the larger community. </p> </li> <li> <p>Findings of this review are limited to a time‐frame of 12 months and prostate volume of 80 mL or less, which may be inadequate to assess the comparative effectiveness of this newer technology. This is reflected in the relevant 2018 American Urological Association guideline (<a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>), which focused on outcomes at follow‐up of 12 months or longer. We hope to see long‐term follow‐up data, including large prostate volume, reported by this study to update this review. </p> </li> <li> <p>Cost‐effectiveness was outside the scope of this review yet it deserves mention that Aquablation requires specialized equipment and considerable capital investment unlike the relatively ubiquitous technology used in TURP. </p> </li> <li> <p>It is of major clinical interest how the effects of Aquablation compare for different prostate sizes. To address this question, we performed and report a predefined subgroup analysis. We could not confirm (based on the published trial protocol) that this analysis was prespecified by the investigators (<a href="http://clinicaltrials.gov/ct2/show/NCT02505919" target="_blank">clinicaltrials.gov/ct2/show/NCT02505919</a>). Due to the risk of spurious findings based on prognostic baseline imbalances, we would downgrade the certainty of evidence for subgroup findings further. </p> </li> <li> <p>Whereas TURP continues to be widely recognised as reference standard when it comes to the surgical management of LUTS in men with BPH, there is increasing interest in alternative procedures that are perceived to be less invasive, for example because they can be performed in an outpatient setting (e.g. PUL; <a href="./references#CD013143-bbs2-0048" title="MagistroG , ChappleCR , ElhilaliM , GillingP , McVaryKT , RoehrbornCG , et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. European Urology2017;72(6):986‐97. [PUBMED: 28734706] ">Magistro 2017</a>), or can be performed in higher‐risk patients on systemic anticoagulation (e.g. HoLEP, photoselective vaporisation of the prostate; <a href="./references#CD013143-bbs2-0023" title="FosterHE , BarryMJ , DahmP , GandhiMC , KaplanSA , KohlerTS , et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. Journal of Urology2018;200(3):612‐9. [PUBMED: 29775639] ">Foster 2018</a>). Direct comparisons, for example of Aquablation and the water vapour thermal therapy would be helpful to compare their comparative effectiveness. Cochrane Reviews for other relevant procedures are ongoing (<a href="./references#CD013143-bbs2-0041" title="KangTW , JungJH , HwangEC , BorofskyM , KimMH , DahmP . Convective radiofrequency water vapor thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2019, Issue 1. [DOI: 10.1002/14651858.CD013251] ">Kang 2019</a>; <a href="./references#CD013143-bbs2-0039" title="JungJH , McCutcheonKA , ReddyB , BorofskyM , NarayanV , KimMH , et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2017, Issue 10. [DOI: 10.1002/14651858.CD012832] ">Jung 2017a</a>; <a href="./references#CD013143-bbs2-0040" title="JungJH , ShinTY , McCutcheonKA , BorofskyM , NarayanV , YoungS , et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD012867] ">Jung 2017b</a>; <a href="./references#CD013143-bbs2-0049" title="MamoulakisC , SofrasF , de laRosetteJ , OmarMI , LamTBL , N'DowJM , et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD009629.pub3] ">Mamoulakis 2014</a>). </p> </li> </ul> </p> </section> <section id="CD013143-sec-0132"> <h3 class="title" id="CD013143-sec-0132">Quality of the evidence</h3> <p>We consistently downgraded the certainty of the evidence to moderate, low or very low. The reasons for downgrading the certainty of the evidence were mainly concerns over study limitations (issues surrounding performance bias and reporting bias), and imprecision (CIs that crossed the assumed thresholds of clinically important differences or few events, or both). For details on the certainty of the evidence, please refer to <a href="./full#CD013143-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD013143-sec-0133"> <h3 class="title" id="CD013143-sec-0133">Potential biases in the review process</h3> <p> <ul id="CD013143-list-0031"> <li> <p>Although we performed this review with a broad search strategy for multiple biomedical databases and the evaluation of the literature, it is possible that additional studies may have been conducted, but not yet published, or that we may not have identified additional studies. </p> </li> <li> <p>The included study (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>), included two different modes of TURP as comparator (i.e. monopolar (55.4%) and bipolar (44.6%)). Whereas the two TURP modalities appear to have similar efficacy and safety (<a href="./references#CD013143-bbs2-0019" title="European Association of Urology. Treatment of non‐neurogenic male LUTS. uroweb.org/guideline/treatment‐of‐non‐neurogenic‐male‐luts/ (accessed 1 March 2018). ">EAU 2017</a>), this could have introduced bias. </p> </li> <li> <p>In the subgroup analysis, we had predefined the prostate volume cut‐off for small and large prostates as 40 mL for this review, but we analysed it using a 50 mL cut‐off because this was a predefined analysis stated by the authors of the included study (<a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] ">Gilling 2018</a>). This may be the source a bias. </p> </li> <li> <p>We could not assess the effect of bias by carrying out a sensitivity analysis since we only included one study. </p> </li> </ul> </p> </section> <section id="CD013143-sec-0134"> <h3 class="title" id="CD013143-sec-0134">Agreements and disagreements with other studies or reviews</h3> <p>Most subject‐related published reviews have been narrative reviews that evaluated the initial results of Aquablation for the treatment LUTS in men with BPH (<a href="./references#CD013143-bbs2-0045" title="LeeR , RoehrbornC . What's new in Aquablation?. European Urology Focus 2018 May 7 [Epub ahead of print]. [DOI: 10.1016/j.euf.2018.04.018] ">Lee 2018</a>; <a href="./references#CD013143-bbs2-0076" title="TaktakS , JonesP , HaqA , RaiBP , SomaniBK . Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. Therapeutic Advances in Urology2018;10(6):183‐8. [PUBMED: 29899759] ">Taktak 2018</a>). These reviews concluded that Aquablation provides reduced resection and overall procedure times, had minimal adverse events (no major complications; i.e. Clavien‐Dindo grades of III or higher), and improved urinary symptom scores and urinary streams while preserving sexual function. This comes from several single‐arm study results. One systematic review (<a href="./references#CD013143-bbs2-0044" title="LebdaiS , ChevrotA , DoiziS , PradereB , DelongchampsNB , BenchikhA , et al. Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment. World Journal of Urology 2018 Jul 2 [Epub ahead of print]. [DOI: 10.1007/s00345‐018‐2368‐6] ">Lebdai 2018</a>), and mini‐review (<a href="./references#CD013143-bbs2-0061" title="RiekenM , Antunes‐LopesT , GeavleteB , MarcelissenT . What is new with sexual side effects after transurethral male lower urinary tract symptom surgery?. European Urology Focus2018;4(1):43‐5. [PUBMED: 29803559] ">Rieken 2018</a>), assessed the loss of ejaculation and erectile dysfunction after surgical treatment for BPH. Both concluded that Aquablation seems to be a reasonable option for those concerned with sexual dysfunction but also labelled the need for longer‐term data. A systematic review for the National Institute for Health and Care Excellence (NICE) Interventional Procedures Program found that "the evidence on efficacy is limited in quantity" but was limited to 6 months' follow‐up data available at the time (<a href="./references#CD013143-bbs2-0054" title="Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. https://www.nice.org.uk/guidance/ipg629 (accessed 11 February 2019). ">NICE guidance</a>). </p> <p>Aside from using the most rigorous methodology based on a published protocol, this review stands out by virtue of its assessment of the certainty of the evidence on a per‐outcome basis. This may be particularly important for those outcomes, such as major adverse events, for which we found only very low‐certainty evidence, signalling major uncertainty about the true effect size. Assuming that decision‐makers would consider major adverse events as a critical outcome, any recommendation for or against the use of Aquablation would be based on only very low‐certainty evidence. In addition, this review distinguishes itself from existing reviews by using thresholds for minimally important differences in the interpretation of effect sizes, thereby emphasising clinically important over statistically significant differences. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013143-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="The current AquaBeam console, CPU, and robotic handpiece with an articulating armReproduced with permission from Springer Customer Service Centre GmbH: Springer Nature, Current Urology Reports, Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results, Omid Yassaie, Joshua A. Silverman, Peter J. Gilling, COPYRIGHT 2017" data-id="CD013143-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>The current AquaBeam console, CPU, and robotic handpiece with an articulating arm</p> <p>Reproduced with permission from Springer Customer Service Centre GmbH: Springer Nature, Current Urology Reports, Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Early Results, Omid Yassaie, Joshua A. Silverman, Peter J. Gilling, COPYRIGHT 2017 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013143-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD013143-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD013143-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 1 Urologic symptom scores (IPSS)." data-id="CD013143-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 1 Urologic symptom scores (IPSS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 2 Quality of life (IPSS‐QoL)." data-id="CD013143-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 2 Quality of life (IPSS‐QoL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 3 Major adverse events." data-id="CD013143-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 3 Major adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 4 Retreatment." data-id="CD013143-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 4 Retreatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 5 Erectile function (IIEF; sexually active men only)." data-id="CD013143-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 5 Erectile function (IIEF; sexually active men only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 6 Ejaculatory function (MSHQ‐EjD; sexually active men only)." data-id="CD013143-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 6 Ejaculatory function (MSHQ‐EjD; sexually active men only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 7 Minor adverse events." data-id="CD013143-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 7 Minor adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 8 Acute urinary retention." data-id="CD013143-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 8 Acute urinary retention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 9 Indwelling urinary catheter (hours)." data-id="CD013143-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 9 Indwelling urinary catheter (hours). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 10 Hospital stay (days)." data-id="CD013143-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Aquablation versus TURP (up to 12 months), Outcome 10 Hospital stay (days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 1 Urologic symptom scores (IPSS)." data-id="CD013143-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 1 Urologic symptom scores (IPSS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 2 Quality of life (IPSS‐QoL)." data-id="CD013143-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 2 Quality of life (IPSS‐QoL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 3 Major adverse events." data-id="CD013143-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 3 Major adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 4 Retreatment." data-id="CD013143-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 4 Retreatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 5 Erectile function (IIEF)." data-id="CD013143-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 5 Erectile function (IIEF). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 6 Ejaculatory function (MSHQ‐EjD)." data-id="CD013143-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 6 Ejaculatory function (MSHQ‐EjD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 7 Minor adverse events." data-id="CD013143-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 7 Minor adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 8 Acute urinary retention." data-id="CD013143-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 8 Acute urinary retention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 9 Indwelling urinary catheter (hours)." data-id="CD013143-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 9 Indwelling urinary catheter (hours). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 10 Hospital stay (days)." data-id="CD013143-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Aquablation versus TURP (up to 6 months), Outcome 10 Hospital stay (days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 1 Urologic symptom scores (IPSS) based on age." data-id="CD013143-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 1 Urologic symptom scores (IPSS) based on age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 2 Quality of life (IPSS‐QoL) based on age." data-id="CD013143-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 2 Quality of life (IPSS‐QoL) based on age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 3 Major adverse events based on age." data-id="CD013143-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 3 Major adverse events based on age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 4 Urologic symptom scores (IPSS) based on prostate volume." data-id="CD013143-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 4 Urologic symptom scores (IPSS) based on prostate volume. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 5 Quality of life (IPSS‐QoL) based on prostate volume." data-id="CD013143-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 5 Quality of life (IPSS‐QoL) based on prostate volume. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 6 Major adverse events based on prostate volume." data-id="CD013143-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 6 Major adverse events based on prostate volume. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 7 Urologic symptom scores (IPSS) based on severity of LUTS." data-id="CD013143-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 7 Urologic symptom scores (IPSS) based on severity of LUTS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 8 Quality of life (IPSS‐QoL) based on severity of LUTS." data-id="CD013143-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 8 Quality of life (IPSS‐QoL) based on severity of LUTS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013143-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/urn:x-wiley:14651858:media:CD013143:CD013143-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_t/tCD013143-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 9 Major adverse events based on severity of LUTS." data-id="CD013143-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Aquablation versus TURP (subgroup analyses up to 6 months), Outcome 9 Major adverse events based on severity of LUTS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/media/CDSR/CD013143/image_n/nCD013143-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013143-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aquablation compared to transurethral resection of the prostate for benign prostatic hyperplasia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with benign prostatic hyperplasia (BPH)<br/> <b>Setting:</b> multicenter (17 centres)/ multicountry (Australia 1, New Zealand 1, UK 3, USA 12)<br/> <b>Intervention:</b> Aquablation<br/> <b>Comparison:</b> transurethral resection of the prostate (TURP) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with TURP</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Aquablation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom scores</b><br/> Assessed with: IPSS<br/> Scale from 0 (best: not at all) to 35 (worst: almost always)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean urologic symptom score was −15.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 lower<br/> (2.51 lower to 2.39 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/> Assessed with: IPSS‐QoL<br/> Scale from 0 (best: delighted) to 6 (worst: terrible)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of Life was −3.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.27 higher<br/> (0.24 lower to 0.78 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major adverse events</b><br/> Assessed with: Clavien‐Dindo classification system (Grade III, IV and V complications)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>181<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.31 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 per 1000<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/> (64 fewer to 116 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Retreatment</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>181<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.68<br/> (0.18 to 15.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 more per 1000<br/> (13 fewer to 228 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erectile function</b> (sexually active men only)<br/> Assessed with: IIEF‐EF domain<br/> Scale from 1 (worst; severe erectile dysfunction) to 30 (best; no erectile dysfunction)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean erectile function (sexually active men only) was −2.73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.31 higher<br/> (0.63 lower to 5.25 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ejaculatory function</b> (sexually active men only)<br/> Assessed with: MSHQ‐EjD<br/> Scale from 1 (worst) to 15 (best)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean ejaculatory function (sexually active men only) was −2.642</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.57 higher<br/> (0.6 higher to 4.53 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BPH:</b> benign prostate hyperplasia; <b>CI:</b> confidence interval; <b>EF:</b> erectile function; <b>IIEF:</b> International index of erectile function; <b>IPSS:</b> International prostate symptom score; <b>MD:</b> mean difference; <b>MSHQ‐EjD:</b> Male Sexual Health Questionnaire for Ejaculatory Dysfunction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TURP:</b> transurethral resection of prostate; <b>QoL:</b> quality of life </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for study limitations: high risk of performance and unclear risk of reporting bias.<br/> <sup>b</sup>Downgraded by one level for imprecision: confidence interval crosses assumed threshold of minimal clinically important difference.<br/> <sup>c</sup>Downgraded by two levels for imprecision: wide confidence interval crosses assumed threshold of minimal clinically important difference.<br/> <sup>d</sup>Control group risk estimates come from single estimates of included study control group. Relative effect based on available case analysis.<br/> <sup>e</sup>Downgraded by two levels for study limitations: high risk of performance and attrition bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Aquablation compared to transurethral resection of the prostate for benign prostatic hyperplasia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013143-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study name</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study period (year to year)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting/Country</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description of participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of follow‐up</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IPSS</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Prostate volume</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] "><b>Gilling 2018</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>October 2015‐December 2016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Multicenter (17 centres)/multicountry (Australia, New Zealand, UK, USA)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>LUTS due to BPH in men 45‐80 years of age with a prostate size between 30 and 80 mL (measured with transrectal ultrasound), IPSS ≥ 12, Q<sub>max</sub> &lt; 15mL/s </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aquablation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.0 ± 7.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.9 ± 6.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54.1 ± 16.2</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TURP (monopolar 36 (55.4%), bipolar 29 (44.6%))</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65.8 ± 7.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.2 ± 6.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.8 ± 13.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>BPH:</b> benign prostatic hyperplasia; <b>IPSS:</b> International Prostate Symptom Score; <b>LUTS:</b> low urinary tract symptoms; <b>Q<sub>max</sub>:</b> maximum flow rate; <b>TURP:</b> transurethral resection of prostate </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of included study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013143-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Screened/eligible (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomised (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed (N): efficacy<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed (N): safety<sup>b</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Finishing study (N (%))</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD013143-bbs2-0001" title="A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM system and TURP for the treatment of LUTS. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00010848. Waterjet ablation therapy for endoscopic resection of prostate tissue (WATER). clinicaltrials.gov/ct2/show/NCT02505919. AndersonP . The WATER study clinical results: a subgroup analysis of larger prostates from the phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S58. [PUBMED: 29877793] BarberN . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Urology2018;199(4 Supplement):e832. BarberN , ThomasA , AhoT . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Clinical Urology2018;11(1_suppl):9‐94. [DOI: 10.1177/2051415818773021] BidairM . The water study sexual function results‐a phase III blinded randomized parallel group trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for moderate‐to‐severe LUTS in men with benign prostatic hyperplasia. Journal of Sexual Medicine2018;15(2):S61‐2. [DOI: 10.1016/j.jsxm.2017.11.153] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. Randomized controlled trial of Aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia: one‐year outcomes. Urology 2018 Dec 12 [Epub ahead of print]. [DOI: 10.1016/j.urology.2018.12.002] GillingP , BarberN , BidairM , AndersonP , SuttonM , AhoT , et al. WATER: a double‐blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. Journal of Urology2018;199(5):1252‐61. [DOI: 10.1016/j.juro.2017.12.065] GillingP , RoehrbornC . The WATER study clinical results‐a phase iii blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e1219. GillingP , RoehrbornC . The WATER study‐a phase III blinded randomized trial of Aquablation vs. transurethral resection of the prostate for the treatment of benign prostatic hyperplasia. Journal of Endourology / Endourological Society2017;31(S2):A355. [DOI: 10.1089/end.2017.29029.abstracts] KasivisvanathanV , HussainM . Aquablation versus transurethral resection of the prostate: 1 year United States ‐ cohort outcomes. Canadian Journal of Urology2018;25(3):9317‐22. [PUBMED: 29900819] PlanteM , GillingP , BarberN , BidairM , AndersonP , SuttonM , et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU International 2018 Jun 4 [Epub ahead of print]. [DOI: 10.1111/bju.14426] RoehrbornC , AndersonP , GillingP . The WATER study clinical results‐a subgroup analysis of larger prostates from the Phase III blinded randomized trial of Aquablation versus TURP. BJU International2018;121(S1):12. [DOI: 10.1111/bju.14116] RoehrbornC , GillingP . Outcomes assessment of Aquablation in prostates 50 to 80ml in volume‐a subgroup analysis from the phase III blinded randomized water study comparing Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe LUTS in men with BPH. Journal of Urology2018;199(4 Supplement):e833‐4. RoehrbornC , GillingP . The WATER study clinical results‐a phase III blinded randomized trial of Aquablation vs. TURP with blinded outcome assessment for moderate‐to‐severe LUTS in men with BPH. European Urology Supplements2018;17(2):e1035‐6. [DOI: 10.1016/S1569‐9056(18)31551‐3] RoehrbornC , GillingP . Water study clinical results‐phase III double blind randomized control trial of Aquablation vs. transurethral resection of the prostate for moderate‐to‐severe benign prostatic hyperplasia. Journal of Urology2017;197(4 Supplement):e603‐4. ZornK , BhojaniN , EltermanD , RoehrbornC , GillingP . The WATER study clinical results: a phase 3, blinded, randomized trial of Aquablation vs. transurethral resection of the prostate with blinded outcome assessment for lower urinary tract symptoms. Canadian Urological Association Journal = Journal de l'Association des Urologues du Canada2018;12(6Suppl2):S79. [PUBMED: 29877793] "><b>Gilling 2018</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aquablation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>275/184</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 (98.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TURP monopolar (36 (55.4%), bipolar 29 (44.6%))</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (92.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>184</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>174</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>181</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>177</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TURP:</b> transurethral resection of prostate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The number of participants analysed for urologic symptom scores.<br/> <sup>b</sup>The number of participants with adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants in included study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/full#CD013143-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013143-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aquablation versus TURP (up to 12 months)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Urologic symptom scores (IPSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (IPSS‐QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Retreatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Erectile function (IIEF; sexually active men only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ejaculatory function (MSHQ‐EjD; sexually active men only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Indwelling urinary catheter (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aquablation versus TURP (up to 12 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013143-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aquablation versus TURP (up to 6 months)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Urologic symptom scores (IPSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (IPSS‐QoL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Retreatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Erectile function (IIEF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ejaculatory function (MSHQ‐EjD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Acute urinary retention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Indwelling urinary catheter (hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aquablation versus TURP (up to 6 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013143-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Aquablation versus TURP (subgroup analyses up to 6 months)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Urologic symptom scores (IPSS) based on age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.67 [‐3.97, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Age less than 65 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐6.34, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Age equal to or greater than 65 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐4.12, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (IPSS‐QoL) based on age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.83, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Age less than 65 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.52, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Age equal to or greater than 65 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.23, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major adverse events based on age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.03, 26.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Age less than 65 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.04 [0.35, 105.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Age equal to or greater than 65 years old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Urologic symptom scores (IPSS) based on prostate volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.54 [‐6.44, 3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 prostate volume less than 50 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐2.12, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 prostate volume equal to or greater than 50 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.10 [‐7.45, ‐0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life (IPSS‐QoL) based on prostate volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.78, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 prostate volume less than 50 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.61, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 prostate volume equal to or greater than 50 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.24, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Major adverse events based on prostate volume <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.15, 4.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 prostate volume less than 50 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.27, 19.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 prostate volume equal to or greater than 50 mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.10, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Urologic symptom scores (IPSS) based on severity of LUTS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.45 [‐3.69, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 IPSS less than or equal to 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐5.42, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 IPSS greater than 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.77, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life (IPSS‐QoL) based on severity of LUTS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.70, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 IPSS less than or equal to 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.14, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 IPSS greater than 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.77, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Major adverse events based on severity of LUTS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.26, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 IPSS less than or equal to 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.10, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 IPSS greater than 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.22, 3.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Aquablation versus TURP (subgroup analyses up to 6 months)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013143.pub2/references#CD013143-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013143.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013143-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013143-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013143-note-0001">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD013143-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013143-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013143\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013143\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013143\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013143\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013143\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013143.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013143.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013143.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013143.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013143.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718715537"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013143.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718715541"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013143.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd71f1c19f47a',t:'MTc0MDcxODcxNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 